iAnthus Capital (ITHUF) 10-K 17 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 28, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	IANTHUS CAPITAL HOLDINGS, INC.
Entity Central Index Key	0001643154
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Interactive Data Current	Yes
Entity File Number	000-56228
Entity Tax Identification Number	98-1360810
Entity Address, Address Line One	420 Lexington Avenue
Entity Address, City or Town	Suite 414
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10170
City Area Code	646
Local Phone Number	518-9411
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Document Annual Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	CA
ICFR Auditor Attestation Flag	false
Entity Common Stock, Shares Outstanding		171,718,192
Entity Public Float			$ 188.5000
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	NY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash	$ 13,244	$ 11,015
Restricted cash	3,334	495
Accounts receivable, net of allowance for doubtful accounts of $27 (December 31, 2020 - $401)	3,595	3,351
Prepaid expenses	3,178	3,611
Inventories, net	30,447	25,451
Other current assets	1,603	1,700
Current Assets	55,401	45,623
Investments	568	512
Property, plant and equipment, net	112,634	106,997
Right-of-use assets	30,429	33,083
Other long-term assets	8,650	8,137
Intangible assets, net	139,062	158,781
Total Assets	346,744	353,133
Liabilities and Shareholders' (Deficit) Equity
Accounts payable	13,636	12,089
Accrued and other current liabilities	99,446	55,053
Current portion of long-term debt, net of issuance costs	165,381	157,042
Derivative liabilities	16	245
Current portion of lease liabilities	7,342	7,450
Current Liabilities	285,821	231,879
Long-term debt, net of issuance costs	27,999	14,133
Deferred income tax	27,507	32,122
Long-term portion of lease liabilities	27,814	27,670
Total Liabilities	369,141	305,804
Commitments and Contingencies
Shareholders' Equity
Common shares - no par value. Authorized - unlimited number. 171,718 - issued and outstanding (December 31, 2020 - 171,718 - issued and outstanding)
Shares to be issued	1,531	1,531
Additional paid-in capital	776,462	769,940
Accumulated deficit	(800,390)	(724,142)
Total Shareholders'(Deficit) Equity	(22,397)	47,329
Total Liabilities and Shareholders' Equity	$ 346,744	$ 353,133

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 27	$ 401
Common Stock, Shares Authorized	Unlimited	Unlimited
Common Stock, No Par Value	$ 0	$ 0
Common Stock, Shares, Issued	171,718	171,718
Common Stock, Shares, Outstanding	171,718	171,718

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues, net of discounts	$ 203,018	$ 151,669
Costs and expenses applicable to revenues	(91,735)	(69,829)
Gross profit	111,283	81,840
Operating expenses
Selling, general and administrative expenses	96,967	98,380
Depreciation and amortization	28,927	26,189
Write-downs, recoveries and other charges, net	47	3,698
Impairment loss	7,367	203,464
Total operating expenses	133,308	331,731
Loss from operations	(22,025)	(249,891)
Interest income	517	403
Other income	1,573	1,007
Interest expense	(23,615)	(20,685)
Accretion expense	(9,057)	(16,962)
Provision for debt obligation fee	(1,677)	(13,764)
Gains from change in fair value of financial instruments	285	5,163
Loss before income taxes	(53,999)	(294,729)
Income tax expense	22,249	18,633
Net loss	$ (76,248)	$ (313,362)
Net loss per share - basic and diluted	$ (0.44)	$ (1.83)
Weighted average number of common shares outstanding - basic and diluted	171,718	171,649

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Capital Stock [Member]	Shares to be Issued [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]
Beginning balance, Shares at Dec. 31, 2019		171,643
Beginning balance at Dec. 31, 2019	$ 352,473		$ 1,531	$ 761,722	$ (410,780)
Share issuance – Settlement of outstanding obligations, Shares		75
Share issuance – Settlement of outstanding obligations	193			193
Share-based compensation	11,350			11,350
Other - Warrant issuance	(3,325)			(3,325)
Net loss	(313,362)				(313,362)
Ending balance, Shares at Dec. 31, 2020		171,718
Ending balance at Dec. 31, 2020	47,329		1,531	769,940	(724,142)
Share-based compensation	6,522			6,522
Net loss	(76,248)				(76,248)
Ending balance, Shares at Dec. 31, 2021		171,718
Ending balance at Dec. 31, 2021	$ (22,397)		$ 1,531	$ 776,462	$ (800,390)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (76,248)	$ (313,362)
Adjustments to reconcile net loss to cash provided by (used in) operations:
Interest income	(517)	(403)
Interest expense	23,615	20,685
Accretion expense	9,057	16,962
Debt obligation fees	1,677	13,764
Impairment loss	7,367	203,464
Depreciation and amortization	31,040	27,920
Write-downs, recoveries and other charges, net	47	3,698
Inventory reserve	1,902	0
Share-based compensation	6,522	11,543
Gain from change in fair value of financial instruments	(285)	(5,163)
Income from equity-accounted investments	0	(182)
Deferred income taxes	(4,623)	(4,537)
Change in operating assets and liabilities (Note 16)	16,594	15,783
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	16,148	(9,828)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(19,440)	(13,435)
Acquisition of intangible assets	(959)	(821)
Proceeds from redemption and sale of investment	0	2,481
Proceeds from sale of property, plant and equipment	275	281
Issuance of related party promissory note	(1,194)	(3,246)
NET CASH USED IN INVESTING ACTIVITIES	(21,318)	(14,740)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of debt	11,000	14,737
Debt issuance costs	(694)	(2,230)
Repayment of debt	(68)	(11,250)
NET CASH PROVIDED BY FINANCING ACTIVITIES	10,238	1,257
CASH AND RESTRICTED CASH:
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH DURING THE YEAR	5,068	(23,311)
CASH AND RESTRICTED CASH, BEGINNING OF YEAR	11,510	34,821
CASH AND RESTRICTED CASH, END OF YEAR	$ 16,578	$ 11,510

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Note 1 – Organization and Description of Business iAnthus Capital Holdings, Inc. (“ICH”, or “iAnthus”), together with its consolidated subsidiaries (the “Company”) was incorporated under the laws of British Columbia, Canada, on November 15, 2013. The Company is a vertically-integrated multi-state owner and The Company’s registered office is located at 1055 West Georgia Street, Suite 1500, Vancouver, British Columbia, V6E 4N7, Canada. The Company is listed on the Canadian Securities Exchange (the “CSE”) under the ticker symbol “IAN” and on the OTC Pink Tier, of the OTC Markets Group, Inc. under the symbol “ITHUF.” The Company’s business activities, and the business activities of its subsidiaries, which operate in jurisdictions where the use of marijuana has been legalized under state and local laws, currently are illegal under U.S. federal law. The U.S. Controlled Substances Act classifies marijuana as a Schedule I controlled substance. Any proceeding that may be brought against the Company could have a material adverse effect on the Company’s business plans, financial condition and results of operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2—Summary of Significant Accounting Policies (a) Basis of Presentation The accompanying consolidated financial statements (the “financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These consolidated financial statements are presented in U.S. dollars. The Company is an “emerging growth company,” as defined in Rule 12b-2 Start-ups non-public (b) Going Concern These consolidated financial statements have been prepared under the assumption that the Company will be able to continue its operations and will be able to realize its assets and discharge its liabilities in the normal course of business in the foreseeable future. For the year ended December 31, 2021, the Company reported a net loss of $76.2 million, operating cash inflows of $16.1 million and an accumulated deficit of $800.4 million as of December 31, 2021, including an impairment loss of its intangible assets, right-of-use 12 During the year ended December 31, 2021, due to liquidity constraints, the Company did not make interest payments due to the lenders of the Company’s 13% senior secured convertible debentures (the “Secured Notes”) and the 8% convertible unsecured debentures (the “Unsecured Debentures”) (together the “Lenders”). The Company is currently in default with respect to certain of its l million and $ million of principal amount and $ million and $ million in accrued interest with respect to the Secured Notes and Unsecured Debentures, respectively. In addition, as a result of the default, the Company has accrued additional fees and interest of $ million in excess of the aforementioned amounts. Refer to Note 8 and Note 17 for further discussion. As a result of the March 31, 2020 default, the Board of Directors of the Company (the “Board”) formed a special committee comprising of five independent, non-management directors of the Company (the “Special Committee”) to, among other matters, explore and consider strategic alternatives available to the Company in light of the prospective liquidity requirements of the Company, the condition of the capital markets affecting companies in the cannabis industry, and the rapid change in the state of the economy and capital markets generally caused by the novel coronavirus known as COVID-19 (“COVID-19”), including, but not limited to: • renegotiation of existing financing arrangements and other material contracts, including any amendments, waivers, extensions or similar agreements with the Lenders and/or stakeholders of the Company and/or its subsidiaries that the Special Committee determines are in the best interest of the Company and/or its subsidiaries; • managing available sources of capital, including equity investments or debt financing or refinancing and the terms thereof; • implementing the operational and financial restructuring of the Company and its subsidiaries and their respective businesses, assets and licensure and other rights; and • implementing other potential strategic transactions. The Special Committee engaged Canaccord Genuity Corp. as its financial advisor to assist the Special Committee in analyzing various strategic alternatives to address its capital structure and liquidity challenges. On June 22, 2020, the Company received notice from Gotham Green Admin 1, LLC (the “Collateral Agent”), as collateral agent holding security for the benefit of the holders of the Company’s Secured Notes, with a demand for repayment (the “Demand Letter”) under the Amended and Restated Secured Debenture Purchase Agreement dated October 10, 2019 (the “Secured Notes Purchase Agreement”) of the entire principal amount of the Secured Notes, together with interest, fees, costs and other allowable charges that had accrued or might accrue in accordance with the Secured Notes Purchase Agreement and the other Transacti o On Jul y 10, 2020, the Company and certain of its subsidiaries entered into a restructuring support agreement (as amended, the “Restructuring Support Agreement”) with holders of our Secured Notes (the “Secured Lenders”) and certain holders of our Unsecured Debentures (the “Consenting Unsecured Lenders”) to affect a proposed recapitalization transaction (t million (the “Tranche Four Secured Notes”). Refer Note 17 for further details regarding the proposed transaction. Subject to compliance with the Restructuring Support Agreement, the Secured Lenders and the Consenting Unsecured Lenders will forbear from further exercising any rights or remedies in connection with any events of default of the Company occurring under their respective agreements and will stop any current or pending enforcement actions with respect to the same, including as set forth in the Demand Letter. Pursuant to the terms of the Restructuring Support Agreement, the Recapitalization Transaction will be implemented pursuant to arrangement proceedings (“Arrangement Proceedings”) commenced under the British Columbia Business Corporations Act, or, only, if necessary, the Companies’ Creditors Arrangement Act (Canada) (“CCAA”). Completion of the Recapitalization Transaction through the Arrangement Proceedings is subject to, among other things, requisite stakeholder approval of the plan of arrangement (the “Plan of Arrangement”). On September 14, 2020, the Company held meetings at which the stakeholders approved the Plan of Arrangement. Following the stakeholder vote, on September 25, 2020, the Company attended a court hearing before the Supreme Court of British Columbia (the “Court”) to receive approval of the Plan of Arrangement. On October 5, 2020, the Company received final approval from the Court for the Plan of Arrangement. On November 5, 2020, the Company received a notice of appeal with respect to the final approval for the Plan of Arrangement by the Court, and on January 29, 2021, the appeal was dismissed by the British Columbia Court of Appeal. Because the Company received the necessary approvals of the Plan of Arrangement from the Supreme Court of British Columbia, Secured Lenders, Unsecured Lenders and the holders of the Company’s common shares, options and warrants, the Recapitalization Transaction will be implemented through the British Columbia Business Corporations Act and not the CCAA. The Company may be required to obtain other necessary approvals with respect to the Plan of Arrangement, including approvals by state-level regulators and the CSE (collectively, the “Requisite Approvals”). Specifically, certain of the transactions contemplated by the Recapitalization Transaction have triggered the requirement for an approval by state-level regulators in certain U.S. states with jurisdiction over the licensed cannabis operations of entities owned, in whole or in part, or controlled, directly or indirectly, by the Company in such states. On February 23, 2021, the Nevada Cannabis Compliance Board approved the proposed change of ownership and control of the Company’s wholly-owned subsidiary, GreenMart of Nevada NLV, LLC (“GMNV”), contemplated by the Recapitalization Transaction. On June 17, 2021, the Massachusetts Cannabis Control Commission (the “CCC”) approved the proposed change of ownership and control of the current licenses held by the Company’s wholly-owned subsidiaries, Mayflower Medicinals, Inc. (“Mayflower”) and Cannatech Medicinals, Inc. (“Cannatech”), contemplated by the Recapitalization Transaction (the “June 17 Approval”). On June 15, 2021, the Company and the Lenders agreed to amend the date by which the Recapitalization Transaction pursuant to the Plan of Arrangement is required to be implemented by from June 30, 2021 to August 31, 2021 (the “Outside Date”). On August 12, 2021, Mayflower’s pending application for a Marijuana Establishment retail license for its Allston, Massachusetts retail location (the “Allston Retail License”) was approved by the CCC at its August 2021 such On August 20, 2021, Gotham Green Partners, LLC and Gotham Green Admin 1, LLC (the “Applicants”) filed a Notice of On August 20, 2021, the Vermont Department of Public Safety (the “DPS”) confirmed that DPS does not require prior approval of the Recapitalization Transaction, except for background checks of the prospective new directors and Interim Chief Executive Officer of the Company to be appointed upon the closing of the Recapitalization Transaction , which background checks have been completed. On October 29, 2021, the Florida Department of Health, Office of Medical Marijuana Use (the “OMMU”) approved the proposed change of ownership and control of the Company’s wholly-owned subsidiary, McCrory’s (as defined below) contemplated by the Recapitalization Transaction (the “Variance Request”). On November 19, 2021, a petition (the “Petition”) was filed by certain petitioners (the “Petitioners”) with the OMMU State-level regulatory approvals remain outstanding in Massachusetts, Maryland, New Jersey, New York and Florida as a result of the Petition until there is a final resolution of the Petition and a final agency order is issued by the OMMU. On January 7, 2022, the New Jersey Cannabis Regulatory Commission (“CRC”) approved the Company’s acquisition of 100% of the equity interest in New Jersey license holder MPX New Jersey, LLC (“MPX NJ”). On February 1, 2022, the Company closed on its acquisition of MPX NJ, which resulted in a requirement for prior regulatory approval for the change of beneficial ownership of MPX NJ that would result from the Recapitalization Transaction to be required as a condition to closing under the Restructuring Support Agreement. The Company believes that the financing transactions received to date should provide the necessary funding for the Company to continue as a going concern. However, there can be no assurance that such capital will be available. As such, these material circumstances cast substantial doubt on the Company’s ability to continue as a going concern for a period no less than 12 months from the date of this report. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. (c) Basis of Consolidation The consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries. The accounts of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies. Intercompany accounts and transactions, including all unrealized intercompany gains or losses on transactions have been eliminated. The Company’s subsidiaries and its interests in each are presented below as of December 31, 2021: Name of Entity Place of Incorporation Interest MPX Bioceutical ULC (“MPX ULC”) (1) Canada 100 % MPX Luxembourg SARL (1) Luxembourg 100 % ABACA, Inc. (1) Arizona, USA 100 % Ambary, LLC (1) Arizona, USA 100 % Health For Life, Inc. (1) Arizona, USA 100 % iAnthus Arizona, LLC (“iA AZ”) Arizona, USA 100 % S8 Management, LLC (1) Arizona, USA 100 % S8 Rental Services, LLC (1) Arizona, USA 100 % Soothing Options, Inc. (1) Arizona, USA 100 % The Healing Center Wellness Center, Inc. (“THCWC”) (1) Arizona, USA 100 % Bergamot Properties, LLC Colorado, USA 100 % Scarlet Globemallow, LLC Colorado, USA 100 % iAnthus Capital Management, LLC (“ICM”) Delaware, USA 100 % GHHIA Management, Inc. (“GHHIA”) Florida, USA 100 % GrowHealthy Properties, LLC (“GHP”) Florida, USA 100 % iAnthus Holdings Florida, LLC (“IHF”) Florida, USA 100 % McCrory’s Sunny Hill Nursery, LLC (“McCrory’s”) Florida, USA 100 % iA IT, LLC Illinois, USA 100 % Budding Rose, Inc. (1) Maryland, USA 100 % GreenMart of Maryland, LLC (1) Maryland, USA 100 % LMS Wellness, Benefit, LLC (1) Maryland, USA 100 % Rosebud Organics, Inc. (1) Maryland, USA 100 % Cannatech Medicinals, Inc. (1) Massachusetts, USA 100 % Fall River Development Company, LLC (1) Massachusetts, USA 100 % IMT, LLC (1) Massachusetts, USA 100 % Mayflower Medicinals, Inc. Massachusetts, USA 100 % Pilgrim Rock Management, LLC Massachusetts, USA 100 % CGX Life Sciences, Inc. (“CGX”) (1) Nevada, USA 100 % GreenMart of Nevada NLV, LLC (GMNV) (1) Nevada, USA 100 % iAnthus Northern Nevada, LLC Nevada, USA 100 % GTL Holdings, LLC New Jersey, USA 100 % iA CBD, LLC (“iA CBD”) New Jersey, USA 100 % iAnthus New Jersey, LLC New Jersey, USA 100 % Citiva Medical, LLC (“Citiva”) New York, USA 100 % iAnthus Empire Holdings, LLC New York, USA 100 % FWR, Inc. Vermont, USA 100 % Grassroots Vermont Management Services, LLC Vermont, USA 100 % Pakalolo, LLC Vermont, USA 100 % (1) Entities acquired as a part of the MPX Bioceutical Corporation (“MPX”) acquisition on February 5, 2019 (the “MPX Acquisition”). During the year ended December 31, 2020, the Company dissolved CinG-X (d) Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations regarding future events that are believed to be reasonable under the circumstances. Actual results may differ significantly from these estimates. Significant estimates made by management not (e) Cash and Restricted Cash For purposes of the consolidated balance sheets and the statements of cash flows, cash includes cash and restricted cash amounts held primarily in U.S. dollars. Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of December 31, 2021, the Company held $3.3 million as restricted cash (December 31, 2020—$ millio n), which is mainly related to funds held in escrow from the iAnthus New Jersey, LLC (“INJ”) senior secured bridge notes (“Senior Secured Bridge Notes”). The net proceeds from the Senior Secured Bridge Notes were placed in escrow, and the availability of the funds are subject to drawdown requests that must be approved by the Secured Lenders. The following table summarizes a reconciliation of cash and restricted cash reported within the consolidated balance sheets to such amounts presented in the statements of cash flows: As of December 31, 2021 2020 Cash $ 13,244 $ 11,015 Restricted cash 3,334 495 Total cash and restricted cash presented in the statements of cash flows $ 16,578 $ 11,510 (f) Accounts Receivable Allowances for doubtful accounts receivable are based on the Company’s assessment of the collectability of specific customer balances, which is based upon a review of the customer’s creditworthiness and past collection history. For trade accounts receivable that have characteristics of both a contractual maturity of one year or less , and arose from the sale of goods or services, the Company will write off the specific balance against the allowance for doubtful accounts when it is known that a provided amount will not be collected. (g) Inventories Inventory is comprised of supplies, raw materials, finished goods and work-in-process by-products Net realizable value is determined as the estimated selling price less a reasonable estimate of the costs of completion, disposal, and transportation. At the end of each reporting period, the Company performs an assessment of inventory obsolescence to measure inventory at the lower of cost or net realizable value. Factors considered in determining obsolescence include, but are not limited to, slow-moving inventory or products that can no longer be marketed. As such, any identified slow moving and/or obsolete inventory is written down to its net realizable value through costs and expenses applicable to revenues on the consolidated statements of operations. (h) Investments The Company currently accounts for its equity-accounted investments using the equity method of accounting in accordance with Accounting Standards Codification (“ASC”) 323. The investments are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s investments are adjusted for the Company’s share of income or loss and distributions each reporting period. The carrying value of the Company’s investments are assessed for indicators or impairment at each balance sheet date. The Company applies fair value accounting for its other investments recognized as financial assets that are disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions of market participants. (i) Property, Plant and Equipment Property, plant and equipment are recorded at historical cost net of accumulated depreciation, write-downs and impairment losses. Depreciation is calculated on a straight-line basis over the estimated useful life as follows: Buildings — 25 years Leasehold improvements — over the shorter of the initial term of the underlying lease plus any reasonably assured renewal terms, and the useful life of the asset Production equipment — 5 years Processing equipment — 5 years Sales equipment — 3 - 5 years Office equipment — 3 - 5 years Land — not depreciated When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment and each major component is assigned an appropriate useful life. Gains and losses on disposal of an item are determined by comparing the proceeds from disposal with the carrying amount of the item and are recognized in profit or loss. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred. Significant expenditures, which extend the useful lives of assets or increase productivity, are capitalized. Construction in progress includes construction progress payments, deposits, engineering costs, and other costs directly related to the construction of cultivation, processing or dispensary facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the appropriate class of property, plant and equipment when the assets are available for use, at which point the depreciation of the asset commences. The Company reviews the carrying values of its property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group might not be recoverable. Assets are grouped at the lowest level for which identifiable cash flows are largely independent when testing for, and measuring for, impairment. In performing its review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future cash flows. A liability for the fair value of an asset retirement obligation associated with the retirement of tangible long-lived assets and the associated asset retirement costs are recognized in the period in which the liability and costs are incurred if a reasonable estimate of fair value can be made using a discounted cash flow model. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset and subsequently amortized over the asset’s useful life. The liability is accreted over the period of expected cash outflows. As a result of declining performance of the Company’s CBD business during the year ended December 31, 2021, an impairment test was performed for iA CBD’s long-lived assets as of December 31, 2021. The Company calculated the fair value of the asset group using the income approach, which estimates the present value of future cash flows based on management’s forecast of revenue growth and operating margins. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future cash flows. The Company concluded that the carrying amount of the long-lived assets exceeded the imputed fair value and recorded an impairment loss of $5.5 million for the year ended December 31, 2021 (December 31, 2020—$4.1 million) and impairment loss of less than $0.1 million has been allocated to property, plant and equipment. (j) Leases The Company leases some items of property, plant and equipment, office, cultivation, processing and dispensary space. On the lease commencement date, a lease is classified as a capital lease or an operating lease based on the classification criteria of the lease guidance under U.S. GAAP. As of January 1, 2019, the Company adopted FASB ASC Topic 842 Leases . Upon Depreciation on the ROU asset is calculated as the difference between the expected straight-line rent expense over the lease term less the accretion on the lease liability. As a result of declining performance of the Company’s CBD business during the year million for the year ended December 31, 2021 (December 31, 2020 - $Nil). Refer to Note 4. (k) Intangible Assets Intangible assets with a finite life are recorded at cost and are amortized on a straight-line basis over estimated useful lives. Intangible assets with an indefinite life are not amortized and are assessed annually for impairment, or more frequently if indicators of impairment arise. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. The Company capitalizes certain internal-use Intangible assets mainly comprise of licenses acquired in business combinations. Licenses are amortized over 15 years, which better reflects the useful lives of the assets. Trademarks are amortized over 7 to 15 years, and all other intangible assets with a finite life are amortized over 1 to 5 years. The Company reviews the carrying values of its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group might not be recoverable. Assets are grouped at the lowest level for which identifiable cash flows are largely independent when testing for, and measuring for, impairment. In performing its review for recoverability, the Company estimates the future cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future As a result of declining performance of the Company’s CBD business during the year assets. Goodwill represents the excess of purchase price paid over the fair value of net identifiable assets (tangible and intangible assets) acquired in business combination transactions. Goodwill is not subject to amortization and is tested for impairment annually or more frequently if events or circumstances indicate that the asset might be impaired. The Company performs a qualitative assessment of its reporting units and certain select quantitative calculations against its current long-range plan to determine whether it is more likely than not (a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount. The Company considers persistent and lasting decline in revenue, negative operating cash flows, changes in internal strategic expansion plans, negative developments in the U.S. cannabis regulatory environment at the federal, state and local levels, and a significant continued decline in stock price, among other factors, as part of the qualitative assessment. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances leads to determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. After assessing the totality of events or circumstances, the Company determines if it is not more likely than not that the fair value of a reporting unit is less than its carry amount, then performing the two-step As a result of the decline in the Company’s stock price and market capitalization, the enterprise fair value of the Company exceeded the Company’s market capitalization as of March 31, 2020. In order to align the implied control premium with current general market conditions, the impairment losses recorded for each reporting unit were higher than those indicated by a difference in carrying value and fair value. For the year ended December 31, 2020, the Company recorded an aggregate impairment loss of $199.4 million against its goodwill balance. As of December 31, 2021, the Company’s goodwill balance was $Nil (December 31, 2020 - $Nil). (m) Derivative Liabilities and Long-term Debt The Company’s debt instruments contain a host liability, freestanding warrants and in some instances, an embedded conversion feature. The Company uses the guidance under FASB ASC Topic 815 Derivatives and Hedging paid-in-capital The host debt instrument is initially recorded at its relative fair value in long-term debt. The host debt instrument is accounted for in accordance with guidance applicable to non-convertible Debt Issuance costs are allocated to each instrument (the debt host, embedded conversion feature and/or freestanding warrants) in the same proportion as the proceeds that are allocated to each instrument other than issuance costs directly related to an instrument are allocated to that instrument only. Issuance costs allocated to the debt host instrument are netted against the proceeds allocated to the debt host. Issuance costs allocated to an instrument classified as derivative liability are expensed in the period that they are incurred in the consolidated statements of operations. Issuance costs allocated to freestanding warrants classified in equity are recorded in paid-in-capital. Upon settlement of convertible debt instruments, ASC 470-20 allocate paid-in (n) Income Taxes Income taxes are accounted for under the asset and liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities and net operating loss carryforwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the consolidated statements of operations in the period in which the change is enacted. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company has elected to classify interest and penalties related to income tax liabilities, when applicable, as part of the interest expense in its consolidated statements of operations. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. The Company follows the provisions of ASC Topic 740, Accounting for Income Taxes. more-likely-than-not (o) Revenue Recognition The Company recognizes revenue under the provision of ASC 606—“ Revenue from Contracts with Customers 1. Identify the contract with a customer; 2. Identify the performance obligation(s) in the contract; 3. Determine the transaction price; 4. Allocate the transaction price to the performance obligation(s) in the contract; and 5. Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue from the sale of cannabis is generally recognized when control over the goods has been transferred to the customer. Payment for medical sales is typically due prior to shipment. Payment for wholesale transactions is due within a specified time period as permitted by the underlying agreement and the Company’s credit policy upon the transfer of goods to the customer. The Company generally satisfies its performance obligation and transfers control to the customer upon delivery and acceptance by the customer. Revenue is recorded at the estimated amount of consideration to which the Company expects to be entitled. Substantially all of the Company’s sales are single performance obligations arrangements for which the transaction price is equivalent to the stated price of the products net of any stated discounts applicable at point of sale. Revenue is recognized net of sales incentives and returns, after discounts. (p) Costs and Expenses Applicable to Revenues Costs and expenses applicable to revenues represents costs directly related to processing and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, and shipping and handling. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and property taxes. The Company recognizes the costs and expenses applicable to revenues at the time the related revenues are recognized. (q) Foreign Currency Translation The functional and reporting currency of the Company is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the foreign exchange rates prevailing at the end of the period. Non-monetary (r) Share-based Compensation The Company has a stock option plan. Share-based awards are measured at the fair value of the stock options at the grant date and recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The fair value of options is determined using the Black-Scholes option pricing model which incorporates all market vesting conditions. The number of options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the share-based awards granted shall be based on the number of awards that eventually vest. Amounts recorded for forfeited or expired unexercised options are accounted for in the year of forfeiture. Upon the exercise of stock options, consideration received on the exercise of share-based awards is recorded as paid-in-capital. Share-based compensation expense includes compensation cost for employee and non-employee 718-10-55. The critical assumptions and estimates used in determining the fair value of share-based compensation include: expected life of options, volatility of the Company’s future share price, risk free rate, future dividend yields and estimated forfeitures at the initial grant date. Changes in assumptions used to estimate fair value could result in materially different results. The Company’s policy is to issue new common shares from treasury to satisfy stock

New Accounting Standards and Ac

New Accounting Standards and Accounting Changes	12 Months Ended
	Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]
New Accounting Standards and Accounting Changes	Note 3 - New Accounting Standards and Accounting Changes Adoption of New Accounting Policies In December 2019, the FASB issued Accounting Standards Update (“ASU”) No. 2019-12, 2019-12”). 2019-12 2019-12 In January 2020, the FASB issued ASU 2020-01, Investments 2020-01”), 2020-01 Recently Issued FASB Accounting Standard Updates In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic : Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The update provides an improvement on the accounting for acquired revenue contracts with customers in a business combination by addressing differences and inconsistencies related to the recognition of acquired contract liability, and payment terms and their effect on subsequent revenue recognized by the acquirer. The amendment requires that an entity (acquirer) recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic . At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic as if it had originated the contracts. For public business entities, the update is effective for fiscal years beginning after December , , including interim periods within those fiscal years, while for all other entities, the amendments are effective for fiscal years beginning after December , , including interim periods within those fiscal years. The FASB provides that the guidance be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In , the FASB issued ASU No. 2021-10, Government Assistance (Topic : Disclosures by Business Entities about Government Assistance (“ASU 2021-10”). The update serves to increase transparency in the disclosure and presentation of government assistance, thus, providing comparable and transparent information to investors and other financial statement users to enable them to understand the financial results and prospects for future cash flows. ASU 2021-10 provides some guidance on disclosures including, information about the nature of the transaction, accounting policy applied, significant terms and conditions, as well as commitments and contingencies. The amendments in the update are effective for all entities for fiscal years beginning after December , , with an earlier application also permitted. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In February 2020, the FASB issued 2020-02, No. 2016-02, 2016-13 On August 5, 2020, the FASB issued ASU No. 2020-06, 470-20) 815-40): statements.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Note 4 – Leases The Company mainly leases office space and cannabis cultivation, processing and retail dispensary space. Leases with an The components of lease expense are as follows: Classification Statement of Operation Information Year Ended December 31, 2021 2020 Operating lease costs (1) Selling, general and administrative expenses $ 8,722 $ 8,765 Total lease cost $ 8,722 $ 8,765 (1) Includes short-term leases and variable lease costs for the year ended December 31, 2021 and 2020. Supplemental balance sheet information related to leases are as follows: Balance Sheet Information Classification Year Ended December 31, 2021 2020 Right-of-use Operating leases $ 30,429 $ 33,083 Lease Liabilities Current portion of lease liabilities Operating leases $ 7,342 $ 7,450 Long-term lease liabilities Operating leases 27,814 27,670 Total $ 35,156 $ 35,120 Maturities of lease liabilities for operating leases as of December 31, 2021, were as follows: Operating 2022 $ 7,342 2023 7,367 2024 7,501 2025 7,637 2026 7,439 Thereafter 57,464 Total lease payments $ 94,750 Less: interest expense (59,594 ) Present value of lease liabilities $ 35,156 Weighted-average remaining lease term (years) 11.7 Weighted-average discount rate 19 % The Company entered into multiple sublease agreements during the year ended December 31, 2021, pursuant to which it serves as lessor to the sublessees. The gross rental income and underlying lease expense are presented gross on the Company’s consolidated balance sheets. For the year ended December 31, 2021, the Company recorded sublease income of $0.6 million (December 31, 2020—$Nil), which is included in the other income line on the consolidated statements of operations. The sublease income to be earned over the remaining sublease term was determined to be less than the costs associated with the primary lease held by the Company. As a result, the Company tested its ROU assets of related subleased facilities for impairment and recorded impairment expense of $1.8 million for the year ended December 31, 2021 (December 31, 2020—$Nil). In addition to above, as a result of declining performance of the Company’s CBD business during the year ended December 31, 2021, an impairment test was performed for iA CBD’s long-lived assets as of December 31, 2021 (Note 2). The Company concluded that the carrying amount of the long-lived assets exceeded the imputed fair value and as a result recorded an impairment loss on ROU assets of $0.3 million for the year ended December 31, 2021 (December 31, 2020—$Nil).

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Note 5—Inventories Inventories is comprised of the following items: As of December 31, 2021 2020 (Revised) Supplies $ 6,188 $ 5,010 Raw materials 5,641 7,047 Work in process 11,219 5,710 Finished goods 7,399 7,684 Total $ 30,447 $ 25,451 Inventories are written down for any obsolescence or when the net realizable value considering future events and conditions is less than the carrying value. For the year ended December 31, 2021, the Company recorded $0.4 million (December 31, 2020 – For the year ended December 31, 2021, the Company recorded $1.9 million (December 31, 2020 - $Nil) in costs and expenses applicable to revenues on the consolidated statements of operations for inventory reserves. As of December 31, 2021 and 2020, the Company had inventory reserves of $1.9 million and $Nil, respe cti

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 6—Property , Plant and Equipment As of December 31, 2021 Cost Accumulated Net Book Value Buildings $ 21,502 $ 1,930 $ 19,572 Leasehold improvements 101,966 24,221 77,745 Production equipment 7,678 3,512 4,166 Processing equipment 4,773 3,022 1,751 Sales equipment 1,344 574 770 Office equipment 3,798 1,754 2,044 Land 4,293 — 4,293 Construction in progress 2,293 — 2,293 Total $ 147,647 $ 35,013 $ 112,634 As of December 31, 2020 Cost Accumulated Net Book Value Buildings $ 3,619 $ 754 $ 2,865 Leasehold improvements 82,356 14,325 68,031 Production equipment 6,308 2,292 4,016 Processing equipment 4,369 1,635 2,734 Sales equipment 1,139 421 718 Office equipment 3,504 1,002 2,502 Land 4,293 — 4,293 Construction in progress 21,838 — 21,838 Total $ 127,426 $ 20,429 $ 106,997 For the year ended December 31, 2021, the Company recorded a depreciation expense of $13.5 million (December 31, 2020—$10.7 million). During the year ended December 31, 2021, the Company disposed of property, plant and equipment, amounting to $0.2 million (December 31, 2020—$3.5 million), with net consideration of $0.3 million and a gain of $0.1 million (December 31, 2020—loss of $2.7 million). As a result of declining performance of the Company’s CBD business during the year ended December 31, 2021, an impairment test was performed for iA CBD’s long-lived assets as of December 31, 2021 (Note 2). The Company concluded that the carrying amount of the long-lived assets exceeded the imputed fair value and recorded an impairment loss on property, plant, and equipment of less than $0.1 million for the year ended December 31, 2021 (December 31, 2020 —$Nil).

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 7— Intangible Assets As of December 31, 2021 Cost Accumulated Net Book Value Licenses $ 153,272 $ 33,967 $ 119,305 Trademarks 29,100 12,125 16,975 Other 3,762 980 2,782 $ 186,134 $ 47,072 $ 139,062 As of December 31, 2020 Cost Accumulated Net Book Value Licenses $ 153,273 $ 23,713 $ 129,560 Trademarks 34,620 8,748 25,872 Other 4,034 685 3,349 $ 191,927 $ 33,146 $ 158,781 As a result of declining performance of the Company’s CBD business during the year In December 2018, GMNV, a wholly owned subsidiary was awarded four conditional adult-use adult-use During the year internal-use Amortization expense for the year ended December 31, 2021 and 2020 was $15.4 million and $15.5 million, respectively. The estimated amortization expense for each of the years ended December 31, as follows: 2022 $ 15,375 2023 15,317 2024 15,317 2025 14,410 2026 14,410

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 8—Long -Term Debt Secured Notes (1) May 2019 March 2019 Other Total As of January 1, 2021 $ 115,350 $ 23,240 $ 31,665 $ 920 $ 171,175 Fair value of financial liabilities issued 13,056 — — 160 13,216 Accretion of balance 6,496 793 1,473 295 9,057 Repayment — — — (68 ) (68 ) As of December 31, 2021 $ 134,902 $ 24,033 $ 33,138 $ 1,307 $ 193,380 Secured Notes Stavola May 2019 March Other Total As of January 1, 2020 $ 77,248 $ 10,800 $ 22,471 $ 30,255 $ 1,278 $ 142,052 Fair value of financial liabilities issued 13,072 — — — — 13,072 Accretion of balance 14,691 — 769 1,410 92 16,962 Provision for debt obligation fees 1 10,339 — — — — 10,339 Repayment — (10,800 ) — — (450 ) (11,250 ) As of December 31, 2020 $ 115,350 $ — $ 23,240 $ 31,665 $ 920 $ 171,175 (1) This amount includes the Company’s obligation to pay an exit fee of $10.0 million that accrues interest at a rate of 13% per annum (the “Exit Fee”) under the Secured Notes. As of December 31, 2021, the total and unamortized discount costs were $30.3 million and $3.2 million, respectively (December 31, 2020—$30.3 million and $9.5 million, respectively). As of December 31, 2021, the total and unamortized debt issuance costs were $7.7 million and $2.5 million, respectively (December 31, 2020—$7.0 million and $3.5 million, respectively). As of December 31, 2021, the total interest accrued on both current and long-term debt was $45.6 million (December 31, 2020—$23.3 million). (a) Secured Notes Tranche One On May 14, 2018, the Company issued $40.0 million secured notes (the “Tranche One Secured Notes”) with a maturity date of May14, 2021 initially accrued The Company issued the Tranche One Secured Notes in the principal amount of $40 million to Gotham Green Partners (“GGP”) Senior Secured (“Tranche One”) debt on the closing date. Because the conversion price of $3.08 was less than the stock price, this gave rise to a beneficial conversion feature valued at $7.9 million. The Company recognized this beneficial conversion feature as a debt discount and additional paid in capital on the closing date. The discount to the Tranche One Secured Notes is being amortized to accretion expense until maturity or its earlier repayment or conversion. During the year ended December 31, 2021, the amount of amortization recorded in accretion expense was $1.0 million (December 31, 2020—$2.6 million). The debt host non-convertible The Tranche One Secured Notes were issued with warrants to purchase, in aggregate, up to 6,670,372 common shares of the Company at an exercise price of $3.60 per share (“Equity Warrants”). The Equity Warrants expired on May 14, 2021. In accordance with ASC 815-10, instruments 815-10-15-74, Concurrent with the issuance of the Tranche One Secured Notes, $10.0 million comprising of 3,891,051 units (“Units”) of the Company were issued. Each Unit is comprised of one Class A common share of the Company at $2.57 per share and a warrant to purchase one Class A share of the Company at an exercise price of $3.86 per share (“Warrants”). The Warrants expired on May 14, 2021. In accordance with ASC 815-10, paid-in-capital The fair values of the debt host contract, Equity Warrants and the Warrants were estimated using the Black-Scholes model, with a volatility of 88.3%, dividend yield of 0.0% and risk-free rate of 2.0%. Issuance costs of $4.4 million were allocated to each of the instruments in proportion to the total proceeds allocated to each. Any issuance costs directly and distinctly related to a specific instrument were allocated to that instrument only. The fair value of the Class A shares was determined using the closing market price of common shares on the date of issuance as the Class A shares may be exchanged for common shares upon issuance at an exchange ratio of 1:1 All the equity warrants expired on May 14, 2021, The terms of the Tranche One Secured Notes impose certain restrictions on the Company’s operating and financing activities, including certain restrictions on the Company’s ability to: incur certain additional indebtedness; grant liens; make certain dividends and other payment restrictions affecting the Company’s subsidiaries; issue shares or convertible securities; and sell certain assets. The financing is secured by all current and future assets of the Company and the rights of the remaining lenders are subordinate to the Tranche One Secured Notes. As of March 31, 2020, the Company was not in compliance with the market value test and the Company did not make interest payments, therefore in breach of a financial covenant for the Tranche One Secured Notes, Tranche Two Secured Notes (as defined herein), and Tranche Three Secured Notes (as defined herein). Furthermore, the Company was in default on its Secured Notes as of March 31, 2020, and as a result, an event of default occurred on April 4, 2020. This default was triggered on the Company’s long-term debt, which as of December 31, 2021, consisted of $97.5 million and $60.0 million of principal amount and $30.9 million and $9.6 million in accrued interest with respect to the Secured Notes and Unsecured Debentures, respectively. As a result of the default, the Company is classifying the Tranche One Secured Notes, Tranche Two Secured Notes, and Tranche Three Secured Notes as current liabilities on the consolidated balance sheets. As of December 31, 2021, the Company is still in default on the Tranche One Secured Notes, Tranche Two Secured Notes, and Tranche Three Secured Notes due to nonpayment of interest. Further details on the default are disclosed in Note 17. For the year ended December 31, 2021, interest expense of $1.7 million (December 31, 2020 – million in accrued interest (December 31, 2020 – an aggregate principal amount of $10.3 million and $3.5 million in accrued interest). Furthermore, as a result of this default, the Company is classifying the Exit Fee as a current liability on the consolidated balance sheets as of December 31, 2021. On July 10, 2020, the Company entered into the Restructuring Support Agreement ( f Tranche Two On September 30, 2019, the Company issued an additional $20.0 million of secured notes (the “Tranche Two Secured Notes”). The Tranche Two Secured Notes accrue d d on The debt host contract is being accounted for using the guidance applicable to non-convertible debt under ASC 470 and was assigned relative fair value of $17.3 million at issuance. It was recorded on the consolidated balance sheets, net of issuance costs of $0.3 million. During the year ended December 31, 2021, interest expense and accretion expense of $3.2 million and $ 0.7 In accordance 815-10, 815-10-15-74, The fair values of the debt host contract and the Tranche Two Equity Warrants were estimated using the Black-Scholes model, with a volatility of 77.97%, dividend yield of 0.0% and risk-free rate of 1.6%. Issuance costs of $0.3 million were allocated to each of the instruments in proportion to the total proceeds allocated to each. Any issuance costs directly and distinctly related to a specific instrument were allocated to that instrument only. All the equity warrants expired on May 14, 202 and the related balance moved within shareholders’ equity on the consolidated balance sheets. Pursuant to the Restructuring Support Agreement, the principal amount of the Tranche Two Secured Notes will remain outstanding until the closing of the Recapitalization Transaction and interest will continue to accrue at default rate of 16.0% per annum until such time. All terms, restrictions and financial covenants applicable to the Tranche One Secured Notes are also applicable to Tranche Two Secured Notes. Tranche Three On December 20, 2019, the Company issued an additional $36.2 million of secured notes (the “Tranche Three Secured Notes”). The Tranche Three Secured Notes accrued d on The debt host contract is being accounted for using the guidance applicable to non-convertible 5.9 1.6 In accordance with ASC 815-10, 815-10-15-74, The fair value of the debt host contract was determined using the present value of future cash outflows discounted at the estimated market borrowing rate for the Company at the time of borrowing. The fair value of the Tranche Three Equity Warrants was estimated using the Black-Scholes model, with a volatility ranging of 74.6%, dividend yield of 0.0% and risk-free rate of 1.7%. Issuance costs of $0.7 million were allocated to each instrument in proportion to the total proceeds allocated to each. Any issuance costs directly and distinctly related to a specific instrument were allocated to that instrument only. All the equity warrants expired on May 14, 2021, and related balance moved within shareholders’ equity on the consolidated balance sheets. Pursuant to the Restructuring Support Agreement, the principal amount of the Tranche Three Secured Notes will remain outstanding until the closing of the Recapitalization Transaction and interest will continue to accrue at default rate of 16.0% per annum until such time. All terms, restrictions and financial covenants applicable to the Tranche One Secured Notes and Tranche Two Secured Notes are also applicable to Tranche Three Secured Notes. Tranche Four On July 13, 2020, as part of the Recapitalization Transaction, the Company issued an additional $14.7 million as the Tranche Four Secured Notes. The net proceeds of the Tranche Four Secured Notes were placed in escrow, and the availability of the funds are subject to drawdown requests that must be approved by the Secured Lenders, per the terms of the Restructuring Support Agreement. The Tranche Four Secured Notes are subject to a 5.0% original issue discount, accrue interest at 8.0 % and The host debt, classified as a liability, was recognized at the fair value of $12.5 million, net of issuance costs. The debt instrument was recorded on the consolidated balance sheets, net of issuance costs of $2.2 million. Interest is to be paid in kind by adding the interest accrued on the principal amount on the last day of each fiscal quarter (the first such interest payment date being September 30, 2020), and such amount thereafter becoming part of the principal amount and will accrue interest. Interest paid in kind will be payable on the date that all of the principal amount is due and payable. During the year ended December 31, 2021, interest expense of $1.3 million ( December 31, 2020 – $0.6 million) and accretion expense of $0.4 million (December 31, 2020— $0.2 (December 31, 2020—$0.4) of restricted cash in escrow from the Tranche Four Secured Notes. All terms, restrictions, and financial covenants applicable to the Tranche One Secured Notes, Tranche Two Secured Notes, and Tranche Three Secured Notes discussed above, are also applicable to the Tranche Four Secured Notes. The Company remains in default with respect to the Tranche One Secured Notes, Tranche Two Secured Notes and Tranche Three Secured Notes, due to failure to remit applicable interest payments between March 2020 and December 2021. Thus all amounts owing on the Tranche One Secured Notes, Tranche Two Secured Notes and Tranche Three Secured Notes are classified as current liabilities on the consolidated balance sheets. As interest on the Tranche Four Secured notes are paid in kind by adding the accrued amount into the principal, the Company is currently in compliance with the Tranche Four Secured Notes as of December 31, 2021. Therefore, the Tranche Four Secured Notes are classified as long-term liabilities on the consolidated balance sheets. iAnthus New Jersey, LLC Senior Secured Bridge Notes On February 2, 2021, INJ issued an aggregate of $11.0 million of senior secured bridge notes (“Senior Secured Bridge Notes”) which mature on the earlier of (i) February 2, 2023, (ii) the date on which the Company closes a Qualified escrow , and the availability of the funds are subject to drawdown requests that must be approved by the Secured Lenders. The Senior Secured Bridge Notes accrue interest at a rate of 14.0% per annum (increasing to 25.0% per annum in the event of default and decreasing to 8.0% per annum upon the completion of the Company’s Recapitalization Transaction). “Qualified Financing” means a transaction or series of related transactions resulting in net proceeds to the Company of not less than $10 million from the subscription of the Company’s securities, including, but not limited to, a private placement or rights offering. The host debt, classified as a liability, was recognized at the fair value of $10.3 million, net of issuance costs. The debt instrument was recorded on the consolidated balance sheets, net of issuance costs of $0.7 million. Interest is to be paid in kind by adding the interest accrued on the principal amount on the last day of each fiscal quarter (the first such interest payment date being March 31, 2021) and such amount thereafter becoming part of the principal amount and will accrue interest. Interest paid in kind will be payable on the date that all of the principal amount is due and payable. For the year ended December 31, 2021, interest expense of $1.5 million (December 31, 2020—$Nil), and accretion expense of $0.3 million (December 31, 2020—$Nil), were recorded on the consolidated statements of operations. As of December 31, 2021, the Company held $3.3 million (December 31, 2020—$ The Senior Secured Bridge Notes are secured by a security interest in certain assets of INJ. The Company provided a guarantee in respect of all of the obligations of INJ under the Senior Secured Bridge Notes. The Company is currently in compliance with the Senior Secured Bridge Notes as of December 31, 2021. Therefore, the Senior Secured Bridge Notes are classified as long-term liabilities on the consolidated balance sheets. (b) March 2019 Debentures On March 18, 2019, the Company completed a private placement of $35.0 million of unsecured convertible debentures (the “March 2019 Debentures”) and corresponding warrants to purchase 2,177,291 common shares of the Company at an exercise price of $6.43 per share from closing date until March 15, 2022 (“March 2019 Equity Warrants”). The March 2019 Debentures bear interest at a rate of 8.0%, per annum, payable quarterly on the last business day of each fiscal quarter, beginning on March 31, 2019. Interest is paid in cash, shares, or a combination of cash and shares, up to 50%, at the Company’s election. The March 2019 Debentures mature on March 15, 2023. The March 2019 Debentures are convertible into 5,912,159 common shares of the Company at $5.92 per share (“March 2019 Conversion Option”). The holders of the March 2019 Debentures may elect to convert the outstanding principal and accrued unpaid interest, in part or in full, at any time following issuance. The Company may force the conversion of the March 2019 Debentures into common shares of the Company at any time following July 16, 2019, if the daily volume weighted average trading price of the Company’s common shares on the OTC Markets is greater than $10.29 for any ten consecutive trading days. The debt host contract is being accounted for using the guidance applicable to non-convertible In accordance 815-10, 815-10-15-74, The fair value of the debt host contract was determined using the present value of future cash outflows discounted at the estimated market borrowing rate for the Company at the time of borrowing. The fair value of the March 2019 Equity Warrants was estimated using the Black-Scholes model, with a volatility of 74.7%, dividend yield of 0.0% and risk-free rate of 2.4%. Issuance costs of $1.3 million were allocated to each instrument in proportion to the total proceeds allocated to each. Any issuance costs directly and distinctly related to a specific instrument were allocated to that instrument only. In relation to the issuance of the March 2019 Debentures, the Company incurred fees of $1.3 million which comprises $0.7 million in common shares and $0.6 million in cash. Issuance costs were allocated to each instrument in proportion to the total proceeds allocated to each. The terms of the March 2019 Debentures impose certain restrictions on its operating and financing activities, including certain restrictions on the Company’s ability to incur certain additional indebtedness at the subsidiary level. As of December 31, 2021, the Company is still in default on its interest obligations to the holders of the Secured Notes. This default triggered a cross-default on its interest obligations to the holders of the March 2019 Debentures. Further, as a result of this default the Company is classifying the debt as a current liability as the Unsecured Debentures are due on demand. The event of default is applicable to all amounts outstanding under the Unsecured Debentures. (c) May 2019 Debentures On May 2, 2019, the Company completed a private placement of $25.0 million of unsecured convertible debentures (the “May 2019 Debentures”) and corresponding warrants to purchase 1,555,207 common shares of the Company at an exercise price of $6.43 per common share from the closing date until March 15, 2022 (“May 2019 Equity Warrants”). The May 2019 Debentures bear interest at a rate of 8.0%, per annum, payable quarterly on the last business day of each fiscal quarter, beginning on June 30, 2019. Interest is paid in cash, shares, or a combination of cash and shares, up to 50%, at the Company’s election. The May 2019 Debentures mature on March 15, 2023. The May 2019 Debentures are convertible into 4,222,971 common shares of the Company at $5.92 per share (“May 2019 Conversion Option”). The holders of the May 2019 Debentures may elect to convert the outstanding principal and accrued unpaid interest, in part or in full, at any time following issuance. The Company may force the conversion of the May 2019 Debentures into common shares of the Company at any time following September 1, 2019, if the daily volume weighted average trading price of the Company’s common shares on the OTC Markets is greater than $10.29 for any ten consecutive trading days. The debt host contract is being accounted for using the guidance applicable to non-convertible —$2.0 In accordance with ASC 815-10, 815-10-15-74, The fair value of the debt host contract was determined using the present value of future cash outflows discounted at the estimated market borrowing rate for the Company at the time of borrowing. The fair value of the May 2019 Equity Warrants was estimated using the Black-Scholes model, with a volatility of 73.6%, dividend yield of 0.0% and risk-free rate of 2.3%. Issuance costs of $0.4 million were allocated to each instrument in proportion to the total proceeds allocated to each. Any issuance costs directly and distinctly related to a specific instrument were allocated to that instrument only. In relation to the issuance of the May 2019 Debentures, the Company incurred fees of $0.4 million which comprises $0.1 million in common shares and $0.3 million in cash. Issuance costs were allocated to each instrument in The terms of the May 2019 Debentures impose certain restrictions on its operating and financing activities, including certain restrictions on the Company’s ability to incur certain additional indebtedness at the subsidiary level. As of December 31, 2021, the Company is still in default on its interest obligations to the holders of the Secured Notes. This default triggered a cross-default on its interest obligations to the holders of the May 2019 Debentures. Further, as a result of this default the Company is classifying the debt as a current liability as the Unsecured Debentures are due on demand. The event of default is applicable to all amounts outstanding under the Unsecured Debentures. (d) Stavola Trust Note As part of the MPX Acquisition, the Company assumed a long-term note (the “Stavola Trust Note”) of $10.8 million, payable to the Elizabeth Stavola 2016 NV Irrevocable Trust. This trust is for the benefit of a former director and officer of the Company, Elizabeth Stavola, and was

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Share Capital	Note 9—Share Capital (a) Share Capital Au thorized: Unlimited common shares. The shares have no par value. The Company’s common shares are voting and dividend-paying. There were no common share issuances for the year ended December 31 , 2021 . The following is a summary of the common share issuances for the year ended December 31, 2020: • 75 common shares of the Company were issued to settle outstanding obligations, with share issuance costs of $0.2 million. (b) Warrants The following table summarizes certain information in respect of the Company’s warrants: For the Year Ended December 31, 2021 For the Year Ended December 31, 2020 Units Weighted Average Units Weighted Average Warrants outstanding, beginning 49,236 $ 4.06 49,236 $ 4.06 Granted — — — — Exercised — — — — Expired (26,596 ) 3.84 — — Warrants outstanding, ending 22,640 $ 3.56 49,236 $ 4.06 During the year ended December 31, 2021 and 2020, no full share equivalent warrants were granted. During the year ended December 31, 2021 and 2020, no full share equivalent warrants were exercised resulting in no cash proceeds. In addition, during the year ended December 31, 2021, full share equivalent warrants expired were 26,596 (December 31, 2020—Nil). T , and , was $ and $ , respectively. As of December 31, 2021 and 2020, warrants classified as derivative liabilities on the consolidated balance sheets were revalued with the following inputs: December 31, 2021 December 31, 2020 Risk-free interest rate 0.9 % 0.2 % Expected dividend yield 0.0 % 0.0 % Expected volatility 93.7 – % 148.0 % Expected life 0.9 years 0.9 years The Company uses an expected volatility based on its historical trading data. The revaluation of the warrants classified as derivative liabilities resulted in a fair value of less than $0.1 million for these instruments as of December 31, 2021 (December 31, 2020—$0.2 million). As a result of the revaluation, the Company recognized a gain of $0.2 million for the year ended December 31, 2021 (December 31, 2020 – gain of $4.8 million), on the consolidated statements of operations. Full share equivalent warrants outstanding and exercisable are as follows: For the Year Ended December 31, For the Year Ended December 31, Year of expiration Number Weighted Average Number Weighted Average 2021 — $ — 26,596 $ 4.37 2022 20,855 3.47 20,855 3.62 2023 1,785 4.57 1,785 4.57 Warrants outstanding 22,640 $ 3.56 49,236 $ 4.06 (c) Potentially Dilutive Securities The following table summarizes potentially dilutive securities, and the resulting common share equivalents outstanding as of December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Common share options 10,504 11,510 Warrants 22,640 49,236 Secured notes 46,458 46,458 Debentures 10,135 10,135 MPX dilutive instruments (1) 408 408 Total 90,145 117,747 (1) Prior to the MPX Acquisition, MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments. Total potentially dilutive securities does not include the shares that would potentially be issued upon conversion of the accrued interest on the Company’s long-term debt. As of December 31, 2021, this would amount to 16.4 million common shares (December 31, 2020 – (d) Stock Options In November 2015, ICM established the ICM 2015 Equity Compensation Plan (the “Plan”), which was subsequently amended on October 15, 2018. The Plan authorized the issuance of up to 2,000,000 Class A common shares. Options granted generally vest over a period of 3 years, and typically have a life of 10 years. The option price under the Plan is determined at the sole discretion of management and the exercise price of all stock options shall be the higher of the closing price on the grant date, the closing price of the previous trading day before the grant date, or if and when appropriate , the five-day The Company also has a rolling stock option plan (the “ICH Plan”), in which the maximum number of common shares which can be reserved for issuance under the plan is 20.0% of the issued and outstanding common shares of the Company. The exercise price of each option shall not be less than the closing price of the common shares on the trading day immediately preceding the day on which the option is granted, less any discount permitted by the CSE. The following table summarizes certain information in respect of option activity under the Company’s stock option plan: For The Year Ended December 31, 2021 For The Year Ended December 31, 2020 Units Weighted Weighted Units Weighted Weighted Options outstanding, beginning 11,510 $ 4.86 — 19,578 $ 4.80 — Granted — — — 135 0.82 — Exercised — — — — — — Forfeited/Expired (1,006 ) 3.96 — (8,203 ) 4.99 — Options outstanding, ending 10,504 $ 4.95 6.24 11,510 $ 4.86 7.34 During the year ended December 31, 2021, no stock options were granted. During the year ended December 31, 2020, 135 incentive stock options were granted with an exercise price of C$0.82 per common share. No stock options were exercised during the year ended December 31, 2021 and 2020. The aggregate intrinsic value of outstanding options as of December 31, 2021 and 2020, was $Nil and $Nil, respectively. The Company used the Black-Scholes option pr icing model to estimate the fair value of the options at the grant date using the following ranges of assumptions: December 31, 2021 December 31, 2020 Risk-free interest rate — 0.6 % Expected dividend yield — 0.0 % Expected volatility — 85.0 % Expected option life — 7 years The Company uses an expected volatility based on its historical trading data. The related share-based compensation expense for the year ended December 31, 2021 was $6.5 million (December 31, 2020—$11.4 million), and is presented in the selling, general and administrative expenses line on the consolidated statements of operations. As of December 31, 2021, the weighted average period over which compensation cost on non-vested

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Information	Note 10—Segment Information Management, including the Company’s Interim Chief Executive Officer and Interim Chief Operating Officer who, together are considered the Company’s Chief Operating Decision Maker (“CODM”) (as defined in the FASB ASC Topic 280 Segment Reporting), assesses segment performance based on segment revenues and gross margins. Selling, general and administrative expenses, amortization of intangibles, write-downs and other charges, interest income, interest expense, accretion expense and tax (provision) recovery are not allocated to the segments. The Company divides its reportable operating segments primarily by geographic region. The Company has two reportable operating segments: Eastern Region and Western Region. The Eastern Region includes the Company’s operations in Florida, Maryland, Massachusetts, New York, New Jersey, and Vermont. The Western Region includes the Company’s operations in Arizona and Nevada as well as its assets and investments in Colorado. The Company no longer has a presence in New Mexico, as it divested of its investment in the state in October 2020. The two geographic regions are looked at separately by the CODM and Company’s management as the operations within those regions are in different stages of development. The operations comprising the Western Region are more established than those in the Eastern Region. Most of the Company’s financial and operational growth is being driven by the Eastern Region. Both the Eastern Region and the Western Region segments generate revenues from the sale of cannabis products through retail dispensaries as well as wholesale supply agreements. The “Other” category in the disclosure below comprises items not separately identifiable to the two reportable operating segments and are not part of the measures used by the Company when assessing the reportable operating segments’ results. It also includes items related to operating segments of the Company that did not meet the quantitative thresholds under ASC 280-10-50-12 280-10-50-11 consolidation. Reportable Segments Year 2021 2020 Revenues Eastern Region $ 128,979 $ 91,149 Western Region 72,424 57,613 Other (1) 1,615 2,907 Total $ 203,018 $ 151,669 Gross profit Eastern Region $ 84,863 $ 57,549 Western Region 27,877 24,239 Other (1,457 ) 52 Total $ 111,283 $ 81,840 Depreciation and amortization Eastern Region $ 16,885 $ 14,346 Western Region 11,235 11,054 Other 807 789 Total $ 28,927 $ 26,189 Asset impairments and write-downs Eastern Region $ 221 $ 23,299 Western Region — 180,283 Other 7,193 3,580 Total $ 7,414 $ 207,162 Net loss Eastern Region $ 9,128 $ (58,424 ) Western Region (2,792 ) (159,894 ) Other (82,584 ) (95,044 ) Total $ (76,248 ) $ (313,362 ) Purchase of property, plant and equipment Eastern Region $ 17,384 $ 12,486 Western Region 2,024 780 Other 32 169 Total $ 19,440 $ 13,435 Purchase of intangibles Eastern Region $ 100 $ 760 Western Region — — Other 859 61 Total $ 959 $ 821 (1) Revenues from segments below the quantitative thresholds are attributable to an operating segment of the Company that includes revenue from the sale of CBD products throughout the United States. This segment has never met any of the quantitative thresholds for determining reportable segments nor does it meet the qualitative criteria for aggregation with the Company’s reportable segments. As of December 31, 2021 2020 Assets Eastern Region $ 224,105 $ 227,237 Western Region 106,485 109,039 Other 16,154 16,857 Total $ 346,744 $ 353,133 Major Customers Major customers are defined as customers that each individually accounted for greater than % of the Company’s annual revenues. For the years ended December 31, 2021 and 2020, sales were made to any one customer that represented in excess of 10% of the Company’s total revenues. Geographic Information As of December , and , substantially all of the Company’s assets were located in the United States and all of the Company’s revenues were earned in the United States. Disaggregated Revenues The Company disaggregates revenues into categories that depict how the nature, amount, timing and uncertainty of the revenues and cashflows are affected by economic factors. For the years ended December , and , the Company disaggregated its revenues as follows: Year Ended December 31, 2021 2020 Revenue iAnthus branded products $ 117,617 $ 83,688 Third party branded products 64,267 48,024 Wholesale/bulk/other products 21,134 19,957 Total $ 203,018 $ 151,669

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Financial Instruments	Note 11 – Financial Instruments Fair values have been determined for measurement and/or disclosure purposes based on the following methods. The Company characterizes inputs used in determining fair value using a hierarchy that prioritizes inputs depending on the degree to which they are observable. The levels of the fair value hierarchy are as follows: • Level 1 – fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2 – fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and • Level 3 – fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). The carrying values of cash, receivables, payables and accrued liabilities approximate their fair values because of the short- term nature of these financial instruments. Balances due to and due from related parties have no terms and are payable on demand, thus are also considered current and short-term in nature, hence carrying value approximates fair value. The component of the Company’s long-term debt attributed to the host liability is recorded at amortized cost. Investments in debt instruments that are held to maturity are also recorded at amortized cost. The following table summarizes the fair value hierarchy for the Company’s financial assets and financial liabilities that are re-measured As of December 3 1 As of December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Financial Assets Long term investments—other 1 $ 568 $ — $ — $ 568 $ 512 $ — $ — $ 512 Financial Liabilities Derivative liabilities $ — $ — $ 16 $ 16 $ — $ — $ 245 $ 245 (1) Long-term investments – other are included in the investments balance on the consolidated balance sheets. There were no transfers between Level 1, Level 2, and Level 3 within the fair value hierarchy during the year ended December 31, 2021. There was a transfer of long-term investments from Level 3 to Level 1 within the fair value hierarchy during the year ended December 31, 2020. This transfer was related to shares of another company that is now publicly traded and can be valued using listed stock prices. The Company’s other investment as of December 31, 2021 and 2020, is considered to be a Level 1 instrument because it is comprised of shares of a public company, and there is an active market for the shares and observable market data, or inputs are now available. All Level 1 investments are comprised of equity investments which are re-measured The following table summarizes the changes in Level 1 financial assets: Financial Assets Balance as of December 31, 2019 100 Revaluations on Level 1 instruments 412 Balance as of December 31, 2020 $ 512 Revaluations on Level 1 instruments 56 Balance as of December 31, 2021 $ 568 The derivative liabilities related to the convertible debt instruments and freestanding warrants are recorded at fair value estimated using the Black-Scholes option pricing model and is therefore considered to be a Level 3 measurement. Refer Note 9. The following table summarizes the changes in Level 3 financial assets and liabilities: Derivative Liabilities Balance as of December 31, 2019 1,671 Additions 3,325 Revaluations on Level 3 instruments (4,751 ) Balance as of December 31, 2020 $ 245 Revaluations on Level 3 instruments (229 ) Balance as of December 31, 2021 $ 16 The Company’s financial and non-financial impairment The following table summarizes the Company’s long-term debt instruments (Note 8) at their carrying value and fair value: As of December 31, 2021 As of December 31, 2020 Carryin g Fair Value Carryin g Fair Value Unsecured Debentures $ 57,171 $ 64,596 $ 54,905 $ 53,830 Secured Notes 134,902 176,487 115,350 134,609 Other 1,307 1,021 920 924 Total $ 193,380 $ 242,104 $ 171,175 $ 189,363

Commitments

Commitments	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 12 – Commitments In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable The following table summarizes the Company’s contractual obligations and commitments as of December 31, 2021: 2022 2023 2024 2025 2026 Operating leases $ 7,342 $ 7,367 $ 7,501 $ 7,637 $ 7,439 Service contracts 2,705 3 — — — Long-term debt, principal (1) 168,209 12,531 66 16,654 79 Total $ 178,256 $ 19,901 $ 7,567 $ 24,291 $ 7,518 (1) The payment schedule above shows amounts payable if the conversion options are not exercised by the lender of the Company’s convertible debt instruments. The Company’s commitments include employees, consultants and advisors, as well as leases and construction contracts for offices, dispensaries and cultivation facilities in the U.S. and Canada. The Company has certain operating leases with renewal options extending one Line of Credit to Zia Integrated, LLC On May 23, 2019, the Company entered into a line of credit agreement (the “Zia Agreement”) with Zia Integrated, LLC (“Zia”), a cannabis management and consulting firm based in Maryland, permitting Zia drawdowns of up to an aggregate of $15.0 million. For each drawdown made by Zia, a convertible promissory note will be issued to Zia by the Company (the “Convertible Note”). On August 5, 2021, the Company exercised its right to terminate the Zia Agreement and Convertible Note. As such, as of December 31, 2021 , no drawdowns were made on the Zia Agreement and the principal amount on the Convertible Note is $Nil (December 31, 2020 — $Nil). Mutual Termination of Acquisition In September 2019, the Company, through its wholly owned subsidiary, iA Northern Nevada, Inc., entered into an agreement to acquire WSCC Inc. (“Sierra Well”), subject to regulatory approval. Sierra Well operates two dispensaries, two cultivation facilities and one processing facility in Nevada. On July 31, 2020, the Company and Sierra Well announced the mutual termination of the merger agreement previously announced in September 2019. As a result of the prolonged timeline to achieve the necessary conditions to close combined with the adverse market conditions surrounding the industry and broader economy, the Company and Sierra Well agreed that it was in the best of interest of both parties to terminate the transaction.

Contingencies And Guarantees

Contingencies And Guarantees	12 Months Ended
	Dec. 31, 2021
Contingencies And Guarantees [Abstract]
Contingencies And Guarantees	Note 13—Contingencies and Guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. In accordance with the FASB ASC Topic 450 Contingencies, the Company will make a provision for a liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The Company believes it has adequate provisions for any such matters. The Company reviews these provisions in conjunction with any related provisions on assets related to the claims at least quarterly and adjusts these provisions to reflect the impacts of negotiations, settlements, rulings, advice of legal counsel and other pertinent information related to the case. Should developments in any of these matters outlined below cause a change in the Company’s determination as to an unfavorable outcome and result in the need to recognize a material provision, or, should any of these matters result in a final adverse judgment or be settled for significant amounts, they could have a material adverse effect on the Company’s results of operations, cash flows, and financial position in the period or periods in which such a change in determination, settlement or judgment occurs. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. The Company has been named as a defendant in several legal actions and is subject to various risks and contingencies arising in the normal course of business. Based on consultation with counsel, management and legal counsel is of the opinion that the outcome of these uncertainties will not have a material adverse effect on the Company’s financial position. The events that allegedly gave rise to the following claims occurred prior to the Company’s closing of the MPX Acquisition in February 2019 are as follows: • There is a claim from a former consultant against the Company, with respect to alleged consulting fees owed by MPX to the consultant, claiming the right to receive approximately $0.5 million and punitive damages. During the year ended December 31, 2021, the former consultant updated the claim to set forth the total damages claimed, which are $5.4 million, and provided supplemental disclosures which specify total damages sought, which are $167.0 million. On December 13, 2021, the Company and former consultant reached a full and final settlement of $1.5 million which is presented as part of the accrued and other current • There is a claim from two former noteholders against the Company and MPX ULC million; and • There is a claim against the Company, MPX ULC and MPX, with respect to a prior acquisition made by MPX in relation to a subsidiary that was not acquired by the Company as part of the MPX Acquisition, claiming $3.0 million in connection with alleged contractual obligations of MPX. In addition, the Company is currently reviewing the following matters with legal counsel and has not yet determined the range of potential losses: In October 2018, Craig Roberts and Beverly Roberts (the “Roberts”) and the Gary W. Roberts Irrevocable Trust Agreement I, Gary W. Roberts Irrevocable Trust Agreement II, and Gary W. Roberts Irrevocable Trust Agreement III (the “Roberts Trust” and together with the Roberts, the “Roberts Plaintiffs”) filed two separate but similar declaratory judgment actions in the Circuit Court of Palm Beach County, Florida against GrowHealthy Holdings, LLC (“GrowHealthy Holdings”) and the Company in connection with the acquisition of substantially all of GrowHealthy Holdings’ assets by the Company in early 2018. The Roberts Plaintiffs’ sought a declaration that iAnthus must deliver certain share certificates to the Roberts without requiring them to deliver a signed Shareholder Representative Agreement to GrowHealthy Holdings, which delivery was a condition precedent to receiving the iAnthus share certificates and required by the acquisition agreements between GrowHealthy Holdings and the Company. In January 2019, the Circuit Court of Palm Beach County denied the Roberts Plaintiffs’ motion for injunctive relief, and the Roberts Plaintiffs signed and delivered the Shareholder Representative Agreement forms to GrowHealthy Holdings while reserving their rights to continue challenging validity and enforceability of the Shareholder Representative Agreement. The Roberts Plaintiffs thereafter amended their complaints to seek monetary damages in the aggregate amount of $22.0 million plus treble damages. On May 21, 2019, the court issued an interlocutory order directing the Company to deliver the share certificates to the Roberts Plaintiffs, which the Company delivered on June 17, 2019, in accordance with the court’s order. On December 19, 2019, the Company appealed the court’s order directing delivery of the share certificates to the Florida Fourth District Court of Appeal, which appeal was denied per curiam. On October 21, 2019, the Roberts Plaintiffs were granted leave by the Circuit Court of Palm Beach County to amend their complaints in order to add purported claims for civil theft and punitive damages, and on November 22, 2019, the Company moved to dismiss the Roberts Plaintiffs’ amended complaints. On May 1, 2020, the Circuit Court of Palm Beach County heard arguments on the motions to dismiss, and on June 11, 2020, the court issued a written order granting in part and denying in part the Company’s motion to dismiss. Specifically, the order denied the Company’s motion to dismiss for lack of jurisdiction and improper venue; however, the court granted the Company’s motion to dismiss the Roberts Plaintiffs’ claims for specific performance, conversion and civil theft without prejudice. With respect to the claim for conversion and civil theft, the Circuit Court of Palm Beach County provided the Roberts Plaintiffs with leave to amend their respective complaints. On July 10, 2020, the Roberts Plaintiffs filed further amended complaints in each action against the Company including claims for conversion, breach of contract and civil theft including damages in the aggregate amount of $22.0 million plus treble damages, and on August 13, 2020, the Company filed a consolidated motion to dismiss such amended complaints. On October 26, 2020, Circuit Court of Palm Beach County heard argument on the consolidated motion to dismiss, denied the motion and entered an order to that effect on October 28, 2020. Answers on both actions were filed on November 20, 2020 and the parties have commenced discovery. On September 9, 2021, the Roberts Plaintiff filed a motion to consolidate the two separate actions, which motion was granted on October 14, 2021. Trial in this matter is currently scheduled to begin May 9, 2022. On August 6, 2020, Craig and Beverly Roberts filed a lawsuit against Randy Maslow in his individual capacity (the “Maslow Complaint”), alleging a single count of purported conversion. The Maslow Complaint was not served on Randy Maslow until November 25, 2021, and the allegations in the Maslow Complaint are substantially similar to those allegations for purported conversion in the complaints filed against the Company. On March 4, 2020, a security services firm filed a complaint against McCrory’s, GHHIA, GHP, and IHF, collectively, claiming $ million in damages, as a result of an alleged breach of a contractual relationship by McCrory’s, GHHIA, GHP, and IHF. On November 17, 2021, the plaintiff filed a Notice of Voluntary Dismissal without prejudice. On Ap ril 19, 2020, Hi-Med (“Hi-Med”), million, filed a complaint with the United States District Court for the Southern District of New York (the “SDNY”) against the Company and certain of the Company’s current and former directors and officers and other defendants (the “Hi-Med Hi-Med of 10b-5 Hi-Med Hi-Med complaint (the “Hi-Med Hi-Med Hi-Med Hi-Med Hi-Med Hi-Med Hi-Med Hi-Med Hi-Med’s so-ordered Hi-Med’s Hi-Med’s Hi-Med’s Hi-Med’s Hi-Med Hi-Med On April 20, 2020, Donald Finch, a shareholder of the Company, filed a putative class action lawsuit with the SDNY against the Company (the “Class Action Lawsuit”) and is seeking damages for an unspecified amount against the Company, its former Chief Executive Officer, its current Chief Financial Officer and others for alleged false and misleading statements regarding certain proceeds from the issuance of long-term debt, that were held in escrow to make interest payments in the event of default on such long-term debt. On May 5, 2020, Peter Cedeno, another shareholder of the Company, filed a putative class action against the same defendants alleging substantially similar causes of action. On June 16, 2020, four separate motions for consolidation, appointment as lead plaintiff, and approval of lead counsel were filed by Jose Antonio Silva, Robert and Sherri Newblatt, Robert Dankner, and Melvin Fussell. On July 9, 2020, the SDNY issued an order consolidating the Class Action Lawsuit and the Hi-Med so-ordered On July 13, 2020, the Company announced the proposed Recapitalization Transaction. On September 14, 2020, at the meetings of Secured Lenders, Unsecured Debentureholders and the holders of the Company’s common shares, options and warrants (collectively, the “Securityholders”), the Securityholders voted in support of the Recapitalization Transaction. On October 5, 2020, the Company received final approval from the Court for the Plan of Arrangement. Completion of the Recapitalization Transaction is subject to the Company obtaining the Requisite Approvals. As such, no amounts have been accrued with respect to the Recapitalization Transaction. On January 29, 2021, the notice of appeal with respect to the final approval for the Plan of Arrangement received by the Company on November 5, 2020 was dismissed by the British Columbia Court of Appeal. On June 15, 2021, the Company and the Lenders agreed to amend the date by which the Recapitalization Transaction pursuant to the Plan of Arrangement is required to be implemented by from June 30, 2021 to August 31, 2021. On August 20, 2021 date on which any regulatory approval or consent condition to implementation of the Plan of Arrangement is satisfied or waived. On August 24, 2021, the Company and Applicants appeared for a case conference before the OSCJ. At this conference, the OSCJ issued a Stay Order that required the parties to the Restructuring Support Agreement to maintain the status quo until the hearing on September 23, 2021. Specifically, the Stay Order provided that the parties shall remain bound by the Restructuring Support Agreement and not take any steps to advance or impede the regulatory approval process for the closing of the Recapitalization Transaction or otherwise have any communication with the applicable state-level regulators concerning the Recapitalization Transaction or the other counterparties to the Restructuring Support Agreement. On September 23, 2021, the parties appeared before the OSCJ for a hearing on the Application. Following this hearing, the OSCJ issued an endorsement that extended the Stay Order from September 23, 2021 until 48 hours after the release of the OSCJ’s decision on the merits of the Application. On October 12, 2021, the OSCJ issued the Decision. Specifically, the OSCJ granted the declaration sought by the Applicants and ordered that the Outside Date in the Restructuring Support Agreement be extended to the date on which any regulatory approval or consent condition to implementation of the Plan of Arrangement is satisfied or waived. On November 10, 2021, the Company filed a Notice of Appeal with the Ontario Court of Appeal, which remains pending. On July 23, 2020, Blue Sky Realty Corporation filed a putative class action against the Company, the Company’s former Chief Executive Officer, and the Company’s Chief Financial Officer in the OSCJ in Toronto. On September 27, 2021, the OSCJ granted leave for the plaintiff to amend its claim (“Amended Claim”). In the Amended Claim, the plaintiff seeks to certify the proposed class action on behalf of two classes. “Class A” consists of all persons, other than any executive level employee of the Company and their immediate families (“Excluded Persons”), who acquired the Company’s common shares in the secondary market on or after April 12, 2019, and who held some or all of those securities until after the close of trading on April 5, 2020. “Class B” consists of all persons, other than Excluded Persons, who acquired the Company’s common shares prior to April 12, 2019, and who held some or all of those securities until after the close of trading on April 5, 2020. Among other things, the plaintiff alleges statutory and common law misrepresentation, and seeks an unspecified amount of damages together with interest and costs. The plaintiff also alleges common law oppression for releasing certain statements allegedly containing misrepresentations inducing Class B members to hold the Company’s securities beyond April 5, 2020. No certification motion has been scheduled. The Amended Claim also changed the named plaintiff from Blue Sky Realty Corporation to Timothy Kwong. The hearing date for the motion for leave to proceed with a secondary market claim under the Securities Act (Ontario) has been vacated, pending resolution of the plaintiff’s motion to compel the production of certain documents. During the year ended December 31, 2020, the Company filed a statement of claim against Oasis Investments II Master Fund Ltd. (“Oasis”), an Unsecured Debentureholder, in the OSCJ. On July 15, 2020, in connection with the proposed Recapitalization Transaction, the Company agreed to discontinue with prejudice its litigation claim which it made on February 27, 2020 against Oasis (regardless of whether the Recapitalization Transaction is consummated). In response to the Company’s statement of claim, Oasis filed a statement of defense and counterclaim against the Company on March 13, 2020, alleging that the Company breached certain debt covenants and an order directing the Company to immediately repay Oasis its $25,000,000 investment plus applicable interest, expenses and fees, among other damages. In connection with the Recapitalization Transaction, Oasis has agreed, while the Restructuring Support Agreement is in effect, not to take any steps in connection with its counterclaim against the Company. In addition, the Company and Oasis have agreed that the counterclaim by Oasis against the Company will be dismissed as a condition of closing of the Recapitalization Transaction. During the year ended December 31, 2020, the Company received demand letters (the “Employee Demand Letters”) from two former employees, claiming combined damages of $1.2 million. During the year ended December 31, 2021, the Company reached a full and final settlement of less than $0.1 million with one of the employees claiming a total of $0.5 million. On July 15, 2021, the Company reached a full and final settlement of less than $0.3 million with the other employee claiming a total of $0.7 million. On December 16, 2020, MPX NJ filed a complaint against the Company in the Superior Court of New Jersey Chancery Division – Monmouth County seeking preliminary and final injunctive relief. Subsequently, on February 3, 2021, the court issued an order, denying MPX NJ’s request for injunctive relief; provided, however, that the court ordered that the area of the Pleasantville, New Jersey cultivation facility currently growing and/or cultivating cannabis shall remain under the control of MPX NJ and be accessed under the supervision of MPX NJ. On March 11, 2021, MPX NJ, ICM and INJ executed a consent for a final judgement on the matter, which was ordered by the court on On January 13, 2021, a class action complaint was filed against iAnthus Empire Holdings (“IEH”) in the SDNY, alleging violations of the Telephone Consumer Protection Act relating to IEH’s alleged text message marketing. On February 1, 2021, the plaintiff filed a Notice of Dismissal Without Prejudice, dismissing all claims of the named, individual plaintiff and the unnamed members of the alleged class. On April 13, 2021, Sean Zaboroski (“Zaboroski”), a shareholder of the Company, filed a Statement of Claim in the OSCJ for a putative class action lawsuit against the Company, its former Chief Executive Officer, its current Interim Chief Executive Officer, and its current Board of Directors (collectively, the “iAnthus Defendants”) alleging gross negligence on the part of the iAnthus Defendants. By court order dated September 27, 2021, the Statement of Claim filed by Zaboroski was discontinued. On August 19, 2021, Arvin Saloum (“Saloum”), a former consultant of the Company, filed a Demand for Arbitration with the American Arbitration Association against THCWC and iA AZ, claiming a breach of a Consulting and Joint Venture Agreement (the “JV Agreement”) for unpaid consulting fees allegedly owed to Saloum under the JV Agreement. Saloum is claiming damages between $1.0 million and $10.0 million. On September 7, 2021, THCWC and iA AZ filed Objections and Answering Statement to Saloum’s Demand for Arbitration. On November 18, 2021, THCWC and iA AZ filed a Complaint for Declaratory Judgment (“Declaratory Judgment Complaint”) with the Arizona Superior Court, Maricopa County (“ASC”), seeking declarations that: (i) the JV Agreement is void, against public policy and terminable at will; (ii) the JV Agreement is unenforceable and not binding; and (iii) the JV Agreement only applies to sales under the Arizona Medical Marijuana Act. On January 21, 2022, Saloum filed an Answer with Counterclaims in response to the Declaratory Judgment Complaint. The Declaratory Judgment Complaint remains pending before the ASC. The Arbitration Action is stayed, pending resolution of the Declaratory Judgment Complaint.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 14—Related Party Transactions Year Ended 2021 2020 Financial Statement Line Item Accounts receivable $ — $ 140 Other long-term assets 4,552 3,358 Total $ 4,552 $ 3,498 As part of the MPX Acquisition, the Company acquired a related party receivable of $0.7 million due from a company owned by a former director and officer of the Company, Elizabeth Stavola. The related party receivable was converted into a loan facility of up to $10.0 million, which accrues interest at the rate of 16.0%, compounded annually. Interest is due upon maturity of the loan on December 31, 2021. The balance of such facility was $4.6 million as of December 31, 2021 (December 31, 2020 – (Note 17). On June 30, 2017, the Company entered into a loan facility with a former director and officer of the Company, Hadley Ford (“Ford”). The total loan facility was up to C$0.5 million (equivalent to $0.4 million) and accrued interest at the rate of 2.5%. Interest was due upon maturity of the loan on June 30, 2021. As of December – As of December 31, 2020, the related party balance is presented in the accounts receivable line on the consolidated balance sheets. On December 21, 2019, a former director and officer of the Company, Ford, was personally issued a loan by the managing member of Gotham Green Partners (the “Managing Member”), the entity which holds the Secured Notes issued by the Company (Note 6). As of the date of U.S . non-interest

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 —Income Taxes Income tax expense (recoveries) for the years ended December 31, 2021 and 2020 consisted of the following: 2021 2020 Current income tax expense (Revised) Federal $ 21,656 $ 18,799 State 5,216 4,371 Total current income tax expense 26,872 23,170 Deferred income Federal (3,919 ) (3,625 ) State (704 ) (912 ) Total deferred income tax recoveries (4,623 ) (4,537 ) Tot al $ 22,249 $ 18,633 Total income tax expense differed from the amount computed by applying the federal statutory tax rate of 21.0% for the years ended December 31, 2021 and 2020 due to the following: 2021 2020 (Revised) Pretax loss at federal statutory rate $ (11,339 ) $ (61,893 ) State income tax expense, net of federal expense (1,435 ) (2,946 ) Non-deductible 16,516 53,554 True-up of income taxes payable 1,236 1,939 Foreign deferred taxes with no benefit recognized 502 (265 ) Other items (139 ) (409 ) Change in valuation allowance 16,908 28,653 Total income ta x expense $ 22,249 $ 18,633 The tax effects of temporary differences that give rise to significant portions 2021 2020 Deferred income Net operating loss carryforwards $ 37,896 $ 33,788 Interest expense carryforwards 29,038 20,413 Stock based compensation 9,082 7,377 Intangible assets 4,396 4,617 Property, plant and equipment 3,652 1,823 Inventories 670 88 Other items 772 557 85,506 68,663 Valuation allowance (80,070 ) (63,162 ) Deferred income 5,436 5,501 Deferred income Intangibles resulting from acquisitions (32,943 ) (37,623 ) Deferred income (32,943 ) (37,623 ) Net deferred inc ome $ (27,507 ) $ (32,122 ) The Company is subject to taxation in Canada and the United States. As the Company operates in state-level legal cannabis industry within the United States, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable As of December 31, 2021, the Company has Canadian non-capital ) non-cultivator The Company files income tax returns in Canada, Luxembourg, United States and various state and local tax jurisdictions. The Company’s income tax years open to examination for Canadian federal income taxes are from for United States federal income taxes are from income tax

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows Supplemental Information	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Consolidated Statements of Cash Flows Supplemental Information	Note 16 – Consolidated Statements of Cash Flows Supplemental Information (a) Cash payments made on account of: Year Ended December 31, 2021 2020 Income taxes $ 4,497 $ 2,196 Interest 94 164 Year Ended December 31, 2021 2020 Decrease (increase) in: Accounts receivables $ (157) $ 2,801 Prepaid expenses 617 436 Inventories (6,898 ) (5,235 ) Other current assets 623 1,267 Other long-term assets (1,095 ) (12,755 ) Increase (decrease) in: Accounts payable 1,554 (4,107 ) Accrued and other current liabilities 21,950 33,376 $ 16,594 $ 15,783 (c) Depreciation and amortization are comprised of the following: Year Ended December 31, 2021 2020 Property, plant and equipment $ 13,533 $ 10,658 Operating lease right-of-use 2,113 1,731 Intangible assets 15,394 15,531 $ 31,040 $ 27,920 (d) Write-downs and other charges are comprised of the following: Year Ended December 31, 2021 2020 Write-downs : Account receivable (recoveries) provisions, net $ (87 ) $ 861 Investment — 137 Operating lease right-of-use 259 — Property, plant and equipment (125 ) 2,700 $ 47 $ 3,698 (e) Impairments are comprised of th e Year Ended December 31, 2021 2020 Impairment losses : Property, plant and equipment $ 36 $ — Right-of-use 2,161 — Intangible assets 5,170 4,100 Goodwill — 199,364 $ 7,367 $ 203,464 (f) Significant non-cash Year Ended December 31, 2021 2020 Supplemental Cash Flow Information: Cashless exercise of MPX warrants recorded as derivatives $ — $ 3,325 Non-cash 1,279 565 Non-cash 1,471 — Accrued capital expenditures — 256 Non-cash — 414

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 17 - Legal Proceedings Please refer to Note 13 for further discussion. Event of Default and Financial Restructuring The Company is currently in default of the obligations under the Company’s long-term debt as discussed in Note 1. As part of the Restructuring Support Agreement with the Secured Lenders and a majority of the Unsecured Debentureholders, dated July 1 0 Non-Convertible (in ’000s of U.S. dollars) Restructured 1 Interim Financing 2 8% Senior 3 Pro 4 Secured Lenders $ 85,000 $ 14,737 $ 5,000 48.625 % Unsecured Debentureholders — — 15,000 48.625 % Existing Shareholders — — — 2.75 % Total $ 85,000 $ 14,737 $ 20,000 100 % (1) The principal balance of the Secured Notes will be reduced to $85.0 million, which will be increased by the amount of the Interim Financing, which has a first lien, senior secured position over all of the Company’s assets, is non-convertible non-callable (2) The Secured Lenders provided $14.7 million of interim financing (“Interim Financing”) to ICM on substantially the same terms as the Restructured Senior Debt, net of a 5% original issue discount. The amounts of the Interim Financing along with any accrued interest thereon is expected to be converted into, and the original principal balance will be added to, the Restructured Senior Debt upon consummation of the Recapitalization Transaction. (3) The 8% Senior Unsecured Debentures include payment in kind at an interest rate of 8% per annum, a maturity date which will be five years after the consummation of the Recapitalization Transaction, are non-callable (4) On January 6, 2022, our Board of Directors approved the terms of a Long-Term Incentive Program recommended by the Board of Director’s compensation committee and, pursuant to which, we will allocate to certain of our employees (including executive officers) restricted stock units and option awards up to, in the aggregate, 5.75% of the fully diluted equity of the Company under the Company’s Amended and Restated Omnibus Incentive Plan dated October 15, 2018 (“LTIP Awards”) in order to attract and retain such employees. The allocations of the LTIP Awards are contingent upon, and will occur within ten days following, the closing of the Recapitalization Transaction contemplated by the Restructuring Support Agreement. All of the Company’s existing warrants and options will be cancelled and the Company’s common shares may be consolidated pursuant to a consolidation ratio which has yet to be determined. Upon consummation of the Recapitalization Transaction, a new board of directors (the “New Board”) will be composed of the following members: (i) three nominees will be designated by the Secured Lenders; (ii) three nominees will be designated by the Consenting Unsecured Lenders; and (iii) one nominee will be designated by the director nominees of the Secured Lenders and Consenting Unsecured Lenders to serve as a member of the Company’s New Board. Pursuant to the terms of the proposed Recapitalization Transaction, the Collateral Agent, the Secured Lenders and the Consenting Unsecured Lenders agreed to forbear from further exercising any rights or remedies in connection with any events of default that now exist or may in the future arise under any of the purchase agreements with respect of the Secured Notes and all other agreements delivered in connection therewith, the purchase agreements with respect of the Unsecured Lenders and all other agreements delivered in connection therewith and any other agreement to which the Collateral Agent, Secured Lenders, or Consenting Unsecured Lenders are a party to (collectively, the “Defaults”) and shall take such steps as are necessary to stop any ongoing enforcement efforts in relation thereto. Upon consummation of the Recapitalization Transaction, the Collateral Agent, Secured Lenders and Consenting Unsecured Lenders are also expected to irrevocably waive all Defaults and take all steps required to withdraw, revoke and/or terminate any enforcement efforts in relation thereto. State-level regulatory approvals remain outstanding in Massachusetts, Maryland, New Jersey, New York and Florida as a result of the Petition until there is a final resolution of the Petition and a final agency order is issued by the OMMU. On January 7, 2022, the New Jersey CRC approved the Company’s acquisition of 100% of the equity interest in New Jersey license holder MPX NJ. On February 1, 2022, the Company closed on its acquisition of MPX NJ, which resulted in a requirement for prior regulatory approval for the change of beneficial ownership of MPX NJ that would result from the Recapitalization Transaction will be required as a condition to closing under the Restructuring Support Agreement. Completion of the Recapitalization Transaction is CCB O utside Date 2021. On August 12, 2021, Mayflower’s pending application for its Allston Retail License was approved by the CCC at its August , 2021 On August 20, 2021, the Vermont DPS confirmed that DPS does not require prior approval of the Recapitalization Transaction, except for background checks of the prospective new directors and Interim Chief Executive Officer of the Company to be appointed upon the closing of the Recapitalization Transaction, which background checks have been completed. On October 29, 2021, the OMMU approved the proposed change of ownership and control of the Company’s wholly-owned subsidiary, McCrory’s, contemplated by the Recapitalization Transaction. On November 19, 2021, the Petition was filed by the Petitioners with the OMMU challenging the OMMU’s approval of the Variance Request and requesting a formal administrative hearing before an administrative law judge at the Florida Division of Administrative Hearings Variance Request is not an enforceable agency order until such time that there is a final resolution of the Petition and a final agency order is issued by the OMMU. On August 20, 2021, the Applicants filed the Application with the OSCJ, which sought, among other things, a declaration that the Outside Date be extended to the date on which any regulatory approval or consent condition to implementation of the Plan of Arrangement is satisfied or waived. On October 12, 2021, the OSCJ issued his decision granting the Applicant’s relief sought in the Decision. Specifically, the OSCJ granted the declaration sought by the Applicants and ordered that the Outside Date in the Restructuring Support Agreement be extended to the date on which any regulatory approval or consent condition to implementation of the Plan of Arrangement is satisfied or waived. On November 10, 2021, the Company filed a Notice of Appeal with the Ontario Court of Appeal, which remains pending. See Note 13 for further discussion. For the year ended December 31, 2021, restructuring costs of $7.4 million (December 31, 2020 – Acquisition of MPX NJ The Company’s wholly-owned subsidiary, INJ, pursuant to a loan agreement (the “Loan Agreement”) with MPX NJ dated October 24, 201 9 equity interest in MPX NJ, which conversion was subject to certain regulatory approvals. In addition, pursuant to an option agreement (the “Option Agreement”) dated as of the same date with MPX NJ and its current equityholders, INJ exercised its option to acquire the remaining 1% of MPX NJ for nominal consideration, again subject to certain regulatory approvals. INJ exercised its rights under the Loan Agreement and Option Agreement on February 3, 2021 and February 25, 2021, respectively. On January 7, 2022, the CRC approved INJ’s acquisition of 100% of the equity interests of MPX NJ. On February 1, 2022, the Company closed on its acquisition of MPX NJ.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The accompanying consolidated financial statements (the “financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These consolidated financial statements are presented in U.S. dollars. The Company is an “emerging growth company,” as defined in Rule 12b-2 Start-ups non-public
Going Concern	(b) Going Concern These consolidated financial statements have been prepared under the assumption that the Company will be able to continue its operations and will be able to realize its assets and discharge its liabilities in the normal course of business in the foreseeable future. For the year ended December 31, 2021, the Company reported a net loss of $76.2 million, operating cash inflows of $16.1 million and an accumulated deficit of $800.4 million as of December 31, 2021, including an impairment loss of its intangible assets, right-of-use 12 During the year ended December 31, 2021, due to liquidity constraints, the Company did not make interest payments due to the lenders of the Company’s 13% senior secured convertible debentures (the “Secured Notes”) and the 8% convertible unsecured debentures (the “Unsecured Debentures”) (together the “Lenders”). The Company is currently in default with respect to certain of its l million and $ million of principal amount and $ million and $ million in accrued interest with respect to the Secured Notes and Unsecured Debentures, respectively. In addition, as a result of the default, the Company has accrued additional fees and interest of $ million in excess of the aforementioned amounts. Refer to Note 8 and Note 17 for further discussion. As a result of the March 31, 2020 default, the Board of Directors of the Company (the “Board”) formed a special committee comprising of five independent, non-management directors of the Company (the “Special Committee”) to, among other matters, explore and consider strategic alternatives available to the Company in light of the prospective liquidity requirements of the Company, the condition of the capital markets affecting companies in the cannabis industry, and the rapid change in the state of the economy and capital markets generally caused by the novel coronavirus known as COVID-19 (“COVID-19”), including, but not limited to: • renegotiation of existing financing arrangements and other material contracts, including any amendments, waivers, extensions or similar agreements with the Lenders and/or stakeholders of the Company and/or its subsidiaries that the Special Committee determines are in the best interest of the Company and/or its subsidiaries; • managing available sources of capital, including equity investments or debt financing or refinancing and the terms thereof; • implementing the operational and financial restructuring of the Company and its subsidiaries and their respective businesses, assets and licensure and other rights; and • implementing other potential strategic transactions. The Special Committee engaged Canaccord Genuity Corp. as its financial advisor to assist the Special Committee in analyzing various strategic alternatives to address its capital structure and liquidity challenges. On June 22, 2020, the Company received notice from Gotham Green Admin 1, LLC (the “Collateral Agent”), as collateral agent holding security for the benefit of the holders of the Company’s Secured Notes, with a demand for repayment (the “Demand Letter”) under the Amended and Restated Secured Debenture Purchase Agreement dated October 10, 2019 (the “Secured Notes Purchase Agreement”) of the entire principal amount of the Secured Notes, together with interest, fees, costs and other allowable charges that had accrued or might accrue in accordance with the Secured Notes Purchase Agreement and the other Transacti o On Jul y 10, 2020, the Company and certain of its subsidiaries entered into a restructuring support agreement (as amended, the “Restructuring Support Agreement”) with holders of our Secured Notes (the “Secured Lenders”) and certain holders of our Unsecured Debentures (the “Consenting Unsecured Lenders”) to affect a proposed recapitalization transaction (t million (the “Tranche Four Secured Notes”). Refer Note 17 for further details regarding the proposed transaction. Subject to compliance with the Restructuring Support Agreement, the Secured Lenders and the Consenting Unsecured Lenders will forbear from further exercising any rights or remedies in connection with any events of default of the Company occurring under their respective agreements and will stop any current or pending enforcement actions with respect to the same, including as set forth in the Demand Letter. Pursuant to the terms of the Restructuring Support Agreement, the Recapitalization Transaction will be implemented pursuant to arrangement proceedings (“Arrangement Proceedings”) commenced under the British Columbia Business Corporations Act, or, only, if necessary, the Companies’ Creditors Arrangement Act (Canada) (“CCAA”). Completion of the Recapitalization Transaction through the Arrangement Proceedings is subject to, among other things, requisite stakeholder approval of the plan of arrangement (the “Plan of Arrangement”). On September 14, 2020, the Company held meetings at which the stakeholders approved the Plan of Arrangement. Following the stakeholder vote, on September 25, 2020, the Company attended a court hearing before the Supreme Court of British Columbia (the “Court”) to receive approval of the Plan of Arrangement. On October 5, 2020, the Company received final approval from the Court for the Plan of Arrangement. On November 5, 2020, the Company received a notice of appeal with respect to the final approval for the Plan of Arrangement by the Court, and on January 29, 2021, the appeal was dismissed by the British Columbia Court of Appeal. Because the Company received the necessary approvals of the Plan of Arrangement from the Supreme Court of British Columbia, Secured Lenders, Unsecured Lenders and the holders of the Company’s common shares, options and warrants, the Recapitalization Transaction will be implemented through the British Columbia Business Corporations Act and not the CCAA. The Company may be required to obtain other necessary approvals with respect to the Plan of Arrangement, including approvals by state-level regulators and the CSE (collectively, the “Requisite Approvals”). Specifically, certain of the transactions contemplated by the Recapitalization Transaction have triggered the requirement for an approval by state-level regulators in certain U.S. states with jurisdiction over the licensed cannabis operations of entities owned, in whole or in part, or controlled, directly or indirectly, by the Company in such states. On February 23, 2021, the Nevada Cannabis Compliance Board approved the proposed change of ownership and control of the Company’s wholly-owned subsidiary, GreenMart of Nevada NLV, LLC (“GMNV”), contemplated by the Recapitalization Transaction. On June 17, 2021, the Massachusetts Cannabis Control Commission (the “CCC”) approved the proposed change of ownership and control of the current licenses held by the Company’s wholly-owned subsidiaries, Mayflower Medicinals, Inc. (“Mayflower”) and Cannatech Medicinals, Inc. (“Cannatech”), contemplated by the Recapitalization Transaction (the “June 17 Approval”). On June 15, 2021, the Company and the Lenders agreed to amend the date by which the Recapitalization Transaction pursuant to the Plan of Arrangement is required to be implemented by from June 30, 2021 to August 31, 2021 (the “Outside Date”). On August 12, 2021, Mayflower’s pending application for a Marijuana Establishment retail license for its Allston, Massachusetts retail location (the “Allston Retail License”) was approved by the CCC at its August 2021 such On August 20, 2021, Gotham Green Partners, LLC and Gotham Green Admin 1, LLC (the “Applicants”) filed a Notice of On August 20, 2021, the Vermont Department of Public Safety (the “DPS”) confirmed that DPS does not require prior approval of the Recapitalization Transaction, except for background checks of the prospective new directors and Interim Chief Executive Officer of the Company to be appointed upon the closing of the Recapitalization Transaction , which background checks have been completed. On October 29, 2021, the Florida Department of Health, Office of Medical Marijuana Use (the “OMMU”) approved the proposed change of ownership and control of the Company’s wholly-owned subsidiary, McCrory’s (as defined below) contemplated by the Recapitalization Transaction (the “Variance Request”). On November 19, 2021, a petition (the “Petition”) was filed by certain petitioners (the “Petitioners”) with the OMMU State-level regulatory approvals remain outstanding in Massachusetts, Maryland, New Jersey, New York and Florida as a result of the Petition until there is a final resolution of the Petition and a final agency order is issued by the OMMU. On January 7, 2022, the New Jersey Cannabis Regulatory Commission (“CRC”) approved the Company’s acquisition of 100% of the equity interest in New Jersey license holder MPX New Jersey, LLC (“MPX NJ”). On February 1, 2022, the Company closed on its acquisition of MPX NJ, which resulted in a requirement for prior regulatory approval for the change of beneficial ownership of MPX NJ that would result from the Recapitalization Transaction to be required as a condition to closing under the Restructuring Support Agreement. The Company believes that the financing transactions received to date should provide the necessary funding for the Company to continue as a going concern. However, there can be no assurance that such capital will be available. As such, these material circumstances cast substantial doubt on the Company’s ability to continue as a going concern for a period no less than 12 months from the date of this report. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Basis of Consolidation	(c) Basis of Consolidation The consolidated financial statements include the accounts of the Company together with its consolidated subsidiaries. The accounts of subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies. Intercompany accounts and transactions, including all unrealized intercompany gains or losses on transactions have been eliminated. The Company’s subsidiaries and its interests in each are presented below as of December 31, 2021: Name of Entity Place of Incorporation Interest MPX Bioceutical ULC (“MPX ULC”) (1) Canada 100 % MPX Luxembourg SARL (1) Luxembourg 100 % ABACA, Inc. (1) Arizona, USA 100 % Ambary, LLC (1) Arizona, USA 100 % Health For Life, Inc. (1) Arizona, USA 100 % iAnthus Arizona, LLC (“iA AZ”) Arizona, USA 100 % S8 Management, LLC (1) Arizona, USA 100 % S8 Rental Services, LLC (1) Arizona, USA 100 % Soothing Options, Inc. (1) Arizona, USA 100 % The Healing Center Wellness Center, Inc. (“THCWC”) (1) Arizona, USA 100 % Bergamot Properties, LLC Colorado, USA 100 % Scarlet Globemallow, LLC Colorado, USA 100 % iAnthus Capital Management, LLC (“ICM”) Delaware, USA 100 % GHHIA Management, Inc. (“GHHIA”) Florida, USA 100 % GrowHealthy Properties, LLC (“GHP”) Florida, USA 100 % iAnthus Holdings Florida, LLC (“IHF”) Florida, USA 100 % McCrory’s Sunny Hill Nursery, LLC (“McCrory’s”) Florida, USA 100 % iA IT, LLC Illinois, USA 100 % Budding Rose, Inc. (1) Maryland, USA 100 % GreenMart of Maryland, LLC (1) Maryland, USA 100 % LMS Wellness, Benefit, LLC (1) Maryland, USA 100 % Rosebud Organics, Inc. (1) Maryland, USA 100 % Cannatech Medicinals, Inc. (1) Massachusetts, USA 100 % Fall River Development Company, LLC (1) Massachusetts, USA 100 % IMT, LLC (1) Massachusetts, USA 100 % Mayflower Medicinals, Inc. Massachusetts, USA 100 % Pilgrim Rock Management, LLC Massachusetts, USA 100 % CGX Life Sciences, Inc. (“CGX”) (1) Nevada, USA 100 % GreenMart of Nevada NLV, LLC (GMNV) (1) Nevada, USA 100 % iAnthus Northern Nevada, LLC Nevada, USA 100 % GTL Holdings, LLC New Jersey, USA 100 % iA CBD, LLC (“iA CBD”) New Jersey, USA 100 % iAnthus New Jersey, LLC New Jersey, USA 100 % Citiva Medical, LLC (“Citiva”) New York, USA 100 % iAnthus Empire Holdings, LLC New York, USA 100 % FWR, Inc. Vermont, USA 100 % Grassroots Vermont Management Services, LLC Vermont, USA 100 % Pakalolo, LLC Vermont, USA 100 % (1) Entities acquired as a part of the MPX Bioceutical Corporation (“MPX”) acquisition on February 5, 2019 (the “MPX Acquisition”). During the year ended December 31, 2020, the Company dissolved CinG-X
Use of Estimates	(d) Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgements that affect the application of accounting policies and the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations regarding future events that are believed to be reasonable under the circumstances. Actual results may differ significantly from these estimates. Significant estimates made by management not
Cash and Restricted Cash	(e) Cash and Restricted Cash For purposes of the consolidated balance sheets and the statements of cash flows, cash includes cash and restricted cash amounts held primarily in U.S. dollars. Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of December 31, 2021, the Company held $3.3 million as restricted cash (December 31, 2020—$ millio n), which is mainly related to funds held in escrow from the iAnthus New Jersey, LLC (“INJ”) senior secured bridge notes (“Senior Secured Bridge Notes”). The net proceeds from the Senior Secured Bridge Notes were placed in escrow, and the availability of the funds are subject to drawdown requests that must be approved by the Secured Lenders. As of December 31, 2021 2020 Cash $ 13,244 $ 11,015 Restricted cash 3,334 495 Total cash and restricted cash presented in the statements of cash flows $ 16,578 $ 11,510
Accounts Receivable	(f) Accounts Receivable Allowances for doubtful accounts receivable are based on the Company’s assessment of the collectability of specific customer balances, which is based upon a review of the customer’s creditworthiness and past collection history. For trade accounts receivable that have characteristics of both a contractual maturity of one year or less , and arose from the sale of goods or services, the Company will write off the specific balance against the allowance for doubtful accounts when it is known that a provided amount will not be collected.
Inventories	(g) Inventories Inventory is comprised of supplies, raw materials, finished goods and work-in-process by-products Net realizable value is determined as the estimated selling price less a reasonable estimate of the costs of completion, disposal, and transportation. At the end of each reporting period, the Company performs an assessment of inventory obsolescence to measure inventory at the lower of cost or net realizable value. Factors considered in determining obsolescence include, but are not limited to, slow-moving inventory or products that can no longer be marketed. As such, any identified slow moving and/or obsolete inventory is written down to its net realizable value through costs and expenses applicable to revenues on the consolidated statements of operations.
Investments	(h) Investments The Company currently accounts for its equity-accounted investments using the equity method of accounting in accordance with Accounting Standards Codification (“ASC”) 323. The investments are initially recognized at cost. Subsequent to initial recognition, the carrying value of the Company’s investments are adjusted for the Company’s share of income or loss and distributions each reporting period. The carrying value of the Company’s investments are assessed for indicators or impairment at each balance sheet date. The Company applies fair value accounting for its other investments recognized as financial assets that are disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets that are required to be recorded at fair value, the Company considers all related factors of the asset by market participants in which the Company would transact and the market-based risk measurements or assumptions of market participants.
Property, Plant and Equipment	(i) Property, Plant and Equipment Property, plant and equipment are recorded at historical cost net of accumulated depreciation, write-downs and impairment losses. Depreciation is calculated on a straight-line basis over the estimated useful life as follows: Buildings — 25 years Leasehold improvements — over the shorter of the initial term of the underlying lease plus any reasonably assured renewal terms, and the useful life of the asset Production equipment — 5 years Processing equipment — 5 years Sales equipment — 3 - 5 years Office equipment — 3 - 5 years Land — not depreciated When significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items or components of property, plant and equipment and each major component is assigned an appropriate useful life. Gains and losses on disposal of an item are determined by comparing the proceeds from disposal with the carrying amount of the item and are recognized in profit or loss. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the respective accounts and any related gain or loss is recognized in the consolidated statements of operations. Maintenance and repairs are charged to expense as incurred. Significant expenditures, which extend the useful lives of assets or increase productivity, are capitalized. Construction in progress includes construction progress payments, deposits, engineering costs, and other costs directly related to the construction of cultivation, processing or dispensary facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the appropriate class of property, plant and equipment when the assets are available for use, at which point the depreciation of the asset commences. The Company reviews the carrying values of its property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group might not be recoverable. Assets are grouped at the lowest level for which identifiable cash flows are largely independent when testing for, and measuring for, impairment. In performing its review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future cash flows. A liability for the fair value of an asset retirement obligation associated with the retirement of tangible long-lived assets and the associated asset retirement costs are recognized in the period in which the liability and costs are incurred if a reasonable estimate of fair value can be made using a discounted cash flow model. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset and subsequently amortized over the asset’s useful life. The liability is accreted over the period of expected cash outflows. As a result of declining performance of the Company’s CBD business during the year ended December 31, 2021, an impairment test was performed for iA CBD’s long-lived assets as of December 31, 2021. The Company calculated the fair value of the asset group using the income approach, which estimates the present value of future cash flows based on management’s forecast of revenue growth and operating margins. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future cash flows. The Company concluded that the carrying amount of the long-lived assets exceeded the imputed fair value and recorded an impairment loss of $5.5 million for the year ended December 31, 2021 (December 31, 2020—$4.1 million) and impairment loss of less than $0.1 million has been allocated to property, plant and equipment.
Leases	(j) Leases The Company leases some items of property, plant and equipment, office, cultivation, processing and dispensary space. On the lease commencement date, a lease is classified as a capital lease or an operating lease based on the classification criteria of the lease guidance under U.S. GAAP. As of January 1, 2019, the Company adopted FASB ASC Topic 842 Leases . Upon Depreciation on the ROU asset is calculated as the difference between the expected straight-line rent expense over the lease term less the accretion on the lease liability. As a result of declining performance of the Company’s CBD business during the year million for the year ended December 31, 2021 (December 31, 2020 - $Nil). Refer to Note 4.
Intangible Assets	(k) Intangible Assets Intangible assets with a finite life are recorded at cost and are amortized on a straight-line basis over estimated useful lives. Intangible assets with an indefinite life are not amortized and are assessed annually for impairment, or more frequently if indicators of impairment arise. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. The Company capitalizes certain internal-use Intangible assets mainly comprise of licenses acquired in business combinations. Licenses are amortized over 15 years, which better reflects the useful lives of the assets. Trademarks are amortized over 7 to 15 years, and all other intangible assets with a finite life are amortized over 1 to 5 years. The Company reviews the carrying values of its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group might not be recoverable. Assets are grouped at the lowest level for which identifiable cash flows are largely independent when testing for, and measuring for, impairment. In performing its review for recoverability, the Company estimates the future cash flows expected to result from the use of the asset or asset group and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset or asset group, an impairment loss is recognized in the consolidated statements of operations. Measurement of the impairment loss is based on the excess of the carrying amount of the asset or asset group over the fair value calculated using discounted expected future As a result of declining performance of the Company’s CBD business during the year assets.
Goodwill	Goodwill represents the excess of purchase price paid over the fair value of net identifiable assets (tangible and intangible assets) acquired in business combination transactions. Goodwill is not subject to amortization and is tested for impairment annually or more frequently if events or circumstances indicate that the asset might be impaired. The Company performs a qualitative assessment of its reporting units and certain select quantitative calculations against its current long-range plan to determine whether it is more likely than not (a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount. The Company considers persistent and lasting decline in revenue, negative operating cash flows, changes in internal strategic expansion plans, negative developments in the U.S. cannabis regulatory environment at the federal, state and local levels, and a significant continued decline in stock price, among other factors, as part of the qualitative assessment. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances leads to determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. After assessing the totality of events or circumstances, the Company determines if it is not more likely than not that the fair value of a reporting unit is less than its carry amount, then performing the two-step As a result of the decline in the Company’s stock price and market capitalization, the enterprise fair value of the Company exceeded the Company’s market capitalization as of March 31, 2020. In order to align the implied control premium with current general market conditions, the impairment losses recorded for each reporting unit were higher than those indicated by a difference in carrying value and fair value. For the year ended December 31, 2020, the Company recorded an aggregate impairment loss of $199.4 million against its goodwill balance. As of December 31, 2021, the Company’s goodwill balance was $Nil (December 31, 2020 - $Nil).
Derivative Liabilities and Long-term Debt	(m) Derivative Liabilities and Long-term Debt The Company’s debt instruments contain a host liability, freestanding warrants and in some instances, an embedded conversion feature. The Company uses the guidance under FASB ASC Topic 815 Derivatives and Hedging paid-in-capital The host debt instrument is initially recorded at its relative fair value in long-term debt. The host debt instrument is accounted for in accordance with guidance applicable to non-convertible Debt Issuance costs are allocated to each instrument (the debt host, embedded conversion feature and/or freestanding warrants) in the same proportion as the proceeds that are allocated to each instrument other than issuance costs directly related to an instrument are allocated to that instrument only. Issuance costs allocated to the debt host instrument are netted against the proceeds allocated to the debt host. Issuance costs allocated to an instrument classified as derivative liability are expensed in the period that they are incurred in the consolidated statements of operations. Issuance costs allocated to freestanding warrants classified in equity are recorded in paid-in-capital. Upon settlement of convertible debt instruments, ASC 470-20 allocate paid-in
Income Taxes	(n) Income Taxes Income taxes are accounted for under the asset and liability method whereby deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the accounting and tax bases of assets and liabilities and net operating loss carryforwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the consolidated statements of operations in the period in which the change is enacted. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company has elected to classify interest and penalties related to income tax liabilities, when applicable, as part of the interest expense in its consolidated statements of operations. The Company is subject to ongoing tax exposures, examinations and assessments in various jurisdictions. Accordingly, the Company may incur additional tax expense based upon the outcomes of such matters. The Company follows the provisions of ASC Topic 740, Accounting for Income Taxes. more-likely-than-not
Revenue Recognition	(o) Revenue Recognition The Company recognizes revenue under the provision of ASC 606—“ Revenue from Contracts with Customers 1. Identify the contract with a customer; 2. Identify the performance obligation(s) in the contract; 3. Determine the transaction price; 4. Allocate the transaction price to the performance obligation(s) in the contract; and 5. Recognize revenue when or as the Company satisfies the performance obligation(s). Revenue from the sale of cannabis is generally recognized when control over the goods has been transferred to the customer. Payment for medical sales is typically due prior to shipment. Payment for wholesale transactions is due within a specified time period as permitted by the underlying agreement and the Company’s credit policy upon the transfer of goods to the customer. The Company generally satisfies its performance obligation and transfers control to the customer upon delivery and acceptance by the customer. Revenue is recorded at the estimated amount of consideration to which the Company expects to be entitled. Substantially all of the Company’s sales are single performance obligations arrangements for which the transaction price is equivalent to the stated price of the products net of any stated discounts applicable at point of sale. Revenue is recognized net of sales incentives and returns, after discounts.
Costs and Expenses Applicable to Revenues	(p) Costs and Expenses Applicable to Revenues Costs and expenses applicable to revenues represents costs directly related to processing and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, and shipping and handling. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and property taxes. The Company recognizes the costs and expenses applicable to revenues at the time the related revenues are recognized.
Foreign Currency Translation	(q) Foreign Currency Translation The functional and reporting currency of the Company is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the foreign exchange rates prevailing at the end of the period. Non-monetary
Share-based Compensation	(r) Share-based Compensation The Company has a stock option plan. Share-based awards are measured at the fair value of the stock options at the grant date and recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The fair value of options is determined using the Black-Scholes option pricing model which incorporates all market vesting conditions. The number of options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the share-based awards granted shall be based on the number of awards that eventually vest. Amounts recorded for forfeited or expired unexercised options are accounted for in the year of forfeiture. Upon the exercise of stock options, consideration received on the exercise of share-based awards is recorded as paid-in-capital. Share-based compensation expense includes compensation cost for employee and non-employee 718-10-55. The critical assumptions and estimates used in determining the fair value of share-based compensation include: expected life of options, volatility of the Company’s future share price, risk free rate, future dividend yields and estimated forfeitures at the initial grant date. Changes in assumptions used to estimate fair value could result in materially different results. The Company’s policy is to issue new common shares from treasury to satisfy stock options which are exercised.
Contingent Liabilities	(s) Contingent Liabilities In accordance with the FASB ASC Topic 450 Contingencies The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Business Combinations	(t) Business Combinations In accordance with the FASB ASC Topic 805 Business Combinations
Beneficial Conversion Feature	(u) Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value at issuance, the Company records a Beneficial Conversion Feature (the “BCF”) and related debt discount. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in
Reclassification	(v) Reclassification Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications adjustment had no effect on the Company’s previously reported consolidated statement of operations and consolidated statements of cash flows. The following table summarizes the effects of reclassification adjustment on the line items within the Company’s consolidated statements of operations: Prior Year’s Line item Reclassified Amount Current Year’s Line item Selling, general and administrative expenses $ 10,658 Depreciation and amortization Amortization of intangibles 15,531 Depreciation and amortization Other losses 169 Other income The following table summarizes the effects of reclassification adjustment on the line items within the Company’s consolidated statements of cash flows: Prior Year’s Line item Reclassified Amount Current Year’s Line item Change in operating assets and liabilities $ 3,246 Net cash used in investing activities
Revision of Prior Period Financial Statements	(w) Revision of Prior Period Financial Statements During the three months ended March 31, 2021, the Company determined that it had not appropriately recorded cost of inventory as of December 31, 2020. This resulted in an overstatement of the inventory balance, accrued and other current liabilities and accumulated deficit as of December 31, 2020, and income tax expense and an understatement of costs and expenses applicable to revenues for the year ended December 31, 2020. Based on an analysis of ASC 250 – “Accounting Changes and Error Corrections,” Staff Accounting Bulletin 99 – “Materiality” and Staff Accounting Bulletin 108 – “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company determined that these errors were immaterial to the previously issued financial statements, and as such no restatement was necessary. Correcting prior period financial statements for immaterial errors would not require previously filed reports to be amended. December 31, 2020 As previously reported Adjustment As adjusted Inventories $ 30,292 $ (4,841 ) $ 25,451 Current assets 50,464 (4,841 ) 45,623 Total assets 357,974 (4,841 ) 353,133 Accrued and other current liabilities 56,381 (1,328 ) 55,053 Current liabilities 233,207 (1,328 ) 231,879 Total liabilities 307,132 (1,328 ) 305,804 Accumulated deficit (720,629 ) (3,513 ) (724,142 ) Total shareholders’ equity 50,842 (3,513 ) 47,329 Total liabilities and shareholders’ equity 357,974 (4,841 ) 353,133 The effect of the adjustments on the line items on the Company’s consolidated statement of operations for the year ended December 31, 2020 was as follows: Year Ended December 31, 2020 As previously reported Adjustment As adjusted Costs and expenses applicable to revenues $ (64,988 ) $ (4,841 ) $ (69,829 ) Gross margin 86,681 (4,841 ) 81,840 Loss from operations (245,050 ) (4,841 ) (249,891 ) Loss from operations before income tax (290,070 ) (4,841 ) (294,911 ) Income tax expense 19,961 (1,328 ) 18,633 Net loss (309,849 ) (3,513 ) (313,362 ) The effect of the adjustments on the line items on the Company’s consolidated statement of cash flow for the year ended December 31, 2020 was as follows: December 31, 2020 As previously reported Adjustment As adjusted Net loss $ (309,849 ) $ (3,513 ) $ (313,362 ) Change in operating assets and liabilities 9,024 3,513 12,537 The effect of the adjustment on the line items within the Company’s inventories as of December 31, 2020 was as follows: December 31, 2020 As previously reported Adjustment As Supplies $ 8,457 $ (3,447 ) $ 5,010 Raw materials 8,857 (1,810 ) 7,047 Work in process 5,737 (27 ) 5,710 Finished goods 7,241 443 7,684 Total $ 30,292 $ (4,841 ) $ 25,451
Coronavirus Pandemic	( x In March 2020, the World Health Organization declared the global emergence of the COVI COVID-19. Any such alterations or modifications could cause substantial interruption to the Company’s business and could have a material adverse effect on the Company’s business, operating results, financial condition, and the trading price of common shares, and could include temporary closures of one or more of the Company’s facilities; temporary or long-term labor shortages; temporary or long-term adverse impacts on the Company’s supply chain and distribution channels; and the potential of increased network vulnerability and risk of data loss resulting from increased use of remote access and removal of data from the Company’s facilities. In addition, COVID-19 It is unknown whether and how the Company may be impacted if the COVID-19 COVID-19 Although, the Company has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it cultivates, processes, manufactures, and sells cannabis during the pendency of the COVID-19 adult-use

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Summary of Subsidiaries	The Company’s subsidiaries and its interests in each are presented below as of December 31, 2021: Name of Entity Place of Incorporation Interest MPX Bioceutical ULC (“MPX ULC”) (1) Canada 100 % MPX Luxembourg SARL (1) Luxembourg 100 % ABACA, Inc. (1) Arizona, USA 100 % Ambary, LLC (1) Arizona, USA 100 % Health For Life, Inc. (1) Arizona, USA 100 % iAnthus Arizona, LLC (“iA AZ”) Arizona, USA 100 % S8 Management, LLC (1) Arizona, USA 100 % S8 Rental Services, LLC (1) Arizona, USA 100 % Soothing Options, Inc. (1) Arizona, USA 100 % The Healing Center Wellness Center, Inc. (“THCWC”) (1) Arizona, USA 100 % Bergamot Properties, LLC Colorado, USA 100 % Scarlet Globemallow, LLC Colorado, USA 100 % iAnthus Capital Management, LLC (“ICM”) Delaware, USA 100 % GHHIA Management, Inc. (“GHHIA”) Florida, USA 100 % GrowHealthy Properties, LLC (“GHP”) Florida, USA 100 % iAnthus Holdings Florida, LLC (“IHF”) Florida, USA 100 % McCrory’s Sunny Hill Nursery, LLC (“McCrory’s”) Florida, USA 100 % iA IT, LLC Illinois, USA 100 % Budding Rose, Inc. (1) Maryland, USA 100 % GreenMart of Maryland, LLC (1) Maryland, USA 100 % LMS Wellness, Benefit, LLC (1) Maryland, USA 100 % Rosebud Organics, Inc. (1) Maryland, USA 100 % Cannatech Medicinals, Inc. (1) Massachusetts, USA 100 % Fall River Development Company, LLC (1) Massachusetts, USA 100 % IMT, LLC (1) Massachusetts, USA 100 % Mayflower Medicinals, Inc. Massachusetts, USA 100 % Pilgrim Rock Management, LLC Massachusetts, USA 100 % CGX Life Sciences, Inc. (“CGX”) (1) Nevada, USA 100 % GreenMart of Nevada NLV, LLC (GMNV) (1) Nevada, USA 100 % iAnthus Northern Nevada, LLC Nevada, USA 100 % GTL Holdings, LLC New Jersey, USA 100 % iA CBD, LLC (“iA CBD”) New Jersey, USA 100 % iAnthus New Jersey, LLC New Jersey, USA 100 % Citiva Medical, LLC (“Citiva”) New York, USA 100 % iAnthus Empire Holdings, LLC New York, USA 100 % FWR, Inc. Vermont, USA 100 % Grassroots Vermont Management Services, LLC Vermont, USA 100 % Pakalolo, LLC Vermont, USA 100 % (1) Entities acquired as a part of the MPX Bioceutical Corporation (“MPX”) acquisition on February 5, 2019 (the “MPX Acquisition”). During the year ended December 31, 2020, the Company dissolved CinG-X
Summary of Cash And Cash Equivalents Restricted Cash And Restricted Cash Equivalents	The following table summarizes a reconciliation of cash and restricted cash reported within the consolidated balance sheets to such amounts presented in the statements of cash flows: As of December 31, 2021 2020 Cash $ 13,244 $ 11,015 Restricted cash 3,334 495 Total cash and restricted cash presented in the statements of cash flows $ 16,578 $ 11,510
Summary of Property Plant And Equipment Useful Life	Property, plant and equipment are recorded at historical cost net of accumulated depreciation, write-downs and impairment losses. Depreciation is calculated on a straight-line basis over the estimated useful life as follows: Buildings — 25 years Leasehold improvements — over the shorter of the initial term of the underlying lease plus any reasonably assured renewal terms, and the useful life of the asset Production equipment — 5 years Processing equipment — 5 years Sales equipment — 3 - 5 years Office equipment — 3 - 5 years Land — not depreciated
Summary of Effects Of Reclassification Adjustment On The Line Items Of Consolidated Statements Of Operations	The following table summarizes the effects of reclassification adjustment on the line items within the Company’s consolidated statements of operations: Prior Year’s Line item Reclassified Amount Current Year’s Line item Selling, general and administrative expenses $ 10,658 Depreciation and amortization Amortization of intangibles 15,531 Depreciation and amortization Other losses 169 Other income
Summary of Effects Of Reclassification Adjustment On The Line Items Of Consolidated Statements Of Cashflows	The following table summarizes the effects of reclassification adjustment on the line items within the Company’s consolidated statements of cash flows: Prior Year’s Line item Reclassified Amount Current Year’s Line item Change in operating assets and liabilities $ 3,246 Net cash used in investing activities
Summary of Effects Of the Adjustment On The Line items Within Consolidated Financial Statements	The following table summarizes the effects of the adjustment on the line items within the Company’s consolidated balance sheet as of December 31, 2020: December 31, 2020 As previously reported Adjustment As adjusted Inventories $ 30,292 $ (4,841 ) $ 25,451 Current assets 50,464 (4,841 ) 45,623 Total assets 357,974 (4,841 ) 353,133 Accrued and other current liabilities 56,381 (1,328 ) 55,053 Current liabilities 233,207 (1,328 ) 231,879 Total liabilities 307,132 (1,328 ) 305,804 Accumulated deficit (720,629 ) (3,513 ) (724,142 ) Total shareholders’ equity 50,842 (3,513 ) 47,329 Total liabilities and shareholders’ equity 357,974 (4,841 ) 353,133 The effect of the adjustments on the line items on the Company’s consolidated statement of operations for the year ended December 31, 2020 was as follows: Year Ended December 31, 2020 As previously reported Adjustment As adjusted Costs and expenses applicable to revenues $ (64,988 ) $ (4,841 ) $ (69,829 ) Gross margin 86,681 (4,841 ) 81,840 Loss from operations (245,050 ) (4,841 ) (249,891 ) Loss from operations before income tax (290,070 ) (4,841 ) (294,911 ) Income tax expense 19,961 (1,328 ) 18,633 Net loss (309,849 ) (3,513 ) (313,362 ) The effect of the adjustments on the line items on the Company’s consolidated statement of cash flow for the year ended December 31, 2020 was as follows: December 31, 2020 As previously reported Adjustment As adjusted Net loss $ (309,849 ) $ (3,513 ) $ (313,362 ) Change in operating assets and liabilities 9,024 3,513 12,537
Summary of Effect Of The Adjsutment On The Line Items Within Inventories	The effect of the adjustment on the line items within the Company’s inventories as of December 31, 2020 was as follows: December 31, 2020 As previously reported Adjustment As Supplies $ 8,457 $ (3,447 ) $ 5,010 Raw materials 8,857 (1,810 ) 7,047 Work in process 5,737 (27 ) 5,710 Finished goods 7,241 443 7,684 Total $ 30,292 $ (4,841 ) $ 25,451

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Summary of Lease Cost	The components of lease expense are as follows: Classification Statement of Operation Information Year Ended December 31, 2021 2020 Operating lease costs (1) Selling, general and administrative expenses $ 8,722 $ 8,765 Total lease cost $ 8,722 $ 8,765 (1) Includes short-term leases and variable lease costs for the year ended December 31, 2021 and 2020.
Summary of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases are as follows: Balance Sheet Information Classification Year Ended December 31, 2021 2020 Right-of-use Operating leases $ 30,429 $ 33,083 Lease Liabilities Current portion of lease liabilities Operating leases $ 7,342 $ 7,450 Long-term lease liabilities Operating leases 27,814 27,670 Total $ 35,156 $ 35,120
Summary of Maturities of Lease Liabilities for Operating Leases	Maturities of lease liabilities for operating leases as of December 31, 2021, were as follows: Operating 2022 $ 7,342 2023 7,367 2024 7,501 2025 7,637 2026 7,439 Thereafter 57,464 Total lease payments $ 94,750 Less: interest expense (59,594 ) Present value of lease liabilities $ 35,156 Weighted-average remaining lease term (years) 11.7 Weighted-average discount rate 19 %

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Summary of inventories	Inventories is comprised of the following items: As of December 31, 2021 2020 (Revised) Supplies $ 6,188 $ 5,010 Raw materials 5,641 7,047 Work in process 11,219 5,710 Finished goods 7,399 7,684 Total $ 30,447 $ 25,451

Property, Plant and Equipment (

Property, Plant and Equipment (Table)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	As of December 31, 2021 Cost Accumulated Net Book Value Buildings $ 21,502 $ 1,930 $ 19,572 Leasehold improvements 101,966 24,221 77,745 Production equipment 7,678 3,512 4,166 Processing equipment 4,773 3,022 1,751 Sales equipment 1,344 574 770 Office equipment 3,798 1,754 2,044 Land 4,293 — 4,293 Construction in progress 2,293 — 2,293 Total $ 147,647 $ 35,013 $ 112,634 As of December 31, 2020 Cost Accumulated Net Book Value Buildings $ 3,619 $ 754 $ 2,865 Leasehold improvements 82,356 14,325 68,031 Production equipment 6,308 2,292 4,016 Processing equipment 4,369 1,635 2,734 Sales equipment 1,139 421 718 Office equipment 3,504 1,002 2,502 Land 4,293 — 4,293 Construction in progress 21,838 — 21,838 Total $ 127,426 $ 20,429 $ 106,997

Intangible Assets (Table)

Intangible Assets (Table)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of other intangible assets	As of December 31, 2021 Cost Accumulated Net Book Value Licenses $ 153,272 $ 33,967 $ 119,305 Trademarks 29,100 12,125 16,975 Other 3,762 980 2,782 $ 186,134 $ 47,072 $ 139,062 As of December 31, 2020 Cost Accumulated Net Book Value Licenses $ 153,273 $ 23,713 $ 129,560 Trademarks 34,620 8,748 25,872 Other 4,034 685 3,349 $ 191,927 $ 33,146 $ 158,781
Summary of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated amortization expense for each of the years ended December 31, as follows: 2022 $ 15,375 2023 15,317 2024 15,317 2025 14,410 2026 14,410

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Summary of Long-term Debt Instruments	Secured Notes (1) May 2019 March 2019 Other Total As of January 1, 2021 $ 115,350 $ 23,240 $ 31,665 $ 920 $ 171,175 Fair value of financial liabilities issued 13,056 — — 160 13,216 Accretion of balance 6,496 793 1,473 295 9,057 Repayment — — — (68 ) (68 ) As of December 31, 2021 $ 134,902 $ 24,033 $ 33,138 $ 1,307 $ 193,380 Secured Notes Stavola May 2019 March Other Total As of January 1, 2020 $ 77,248 $ 10,800 $ 22,471 $ 30,255 $ 1,278 $ 142,052 Fair value of financial liabilities issued 13,072 — — — — 13,072 Accretion of balance 14,691 — 769 1,410 92 16,962 Provision for debt obligation fees 1 10,339 — — — — 10,339 Repayment — (10,800 ) — — (450 ) (11,250 ) As of December 31, 2020 $ 115,350 $ — $ 23,240 $ 31,665 $ 920 $ 171,175 (1) This amount includes the Company’s obligation to pay an exit fee of $10.0 million that accrues interest at a rate of 13% per annum (the “Exit Fee”) under the Secured Notes.

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Summary Of Warrants Activity	The following table summarizes certain information in respect of the Company’s warrants: For the Year Ended December 31, 2021 For the Year Ended December 31, 2020 Units Weighted Average Units Weighted Average Warrants outstanding, beginning 49,236 $ 4.06 49,236 $ 4.06 Granted — — — — Exercised — — — — Expired (26,596 ) 3.84 — — Warrants outstanding, ending 22,640 $ 3.56 49,236 $ 4.06
Summary Of Assumptions Used To Record Fair Value of Warrants	As of December 31, 2021 and 2020, warrants classified as derivative liabilities on the consolidated balance sheets were revalued with the following inputs: December 31, 2021 December 31, 2020 Risk-free interest rate 0.9 % 0.2 % Expected dividend yield 0.0 % 0.0 % Expected volatility 93.7 – % 148.0 % Expected life 0.9 years 0.9 years
Schedule Of Warrants Outstanding	Full share equivalent warrants outstanding and exercisable are as follows: For the Year Ended December 31, For the Year Ended December 31, Year of expiration Number Weighted Average Number Weighted Average 2021 — $ — 26,596 $ 4.37 2022 20,855 3.47 20,855 3.62 2023 1,785 4.57 1,785 4.57 Warrants outstanding 22,640 $ 3.56 49,236 $ 4.06
Summary Of Potentially Dilutive Securities	The following table summarizes potentially dilutive securities, and the resulting common share equivalents outstanding as of December 31, 2021 and 2020: December 31, 2021 December 31, 2020 Common share options 10,504 11,510 Warrants 22,640 49,236 Secured notes 46,458 46,458 Debentures 10,135 10,135 MPX dilutive instruments (1) 408 408 Total 90,145 117,747 (1) Prior to the MPX Acquisition, MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments.
Summary Of Option Activity	The following table summarizes certain information in respect of option activity under the Company’s stock option plan: For The Year Ended December 31, 2021 For The Year Ended December 31, 2020 Units Weighted Weighted Units Weighted Weighted Options outstanding, beginning 11,510 $ 4.86 — 19,578 $ 4.80 — Granted — — — 135 0.82 — Exercised — — — — — — Forfeited/Expired (1,006 ) 3.96 — (8,203 ) 4.99 — Options outstanding, ending 10,504 $ 4.95 6.24 11,510 $ 4.86 7.34

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of Reportable Segments	Year 2021 2020 Revenues Eastern Region $ 128,979 $ 91,149 Western Region 72,424 57,613 Other (1) 1,615 2,907 Total $ 203,018 $ 151,669 Gross profit Eastern Region $ 84,863 $ 57,549 Western Region 27,877 24,239 Other (1,457 ) 52 Total $ 111,283 $ 81,840 Depreciation and amortization Eastern Region $ 16,885 $ 14,346 Western Region 11,235 11,054 Other 807 789 Total $ 28,927 $ 26,189 Asset impairments and write-downs Eastern Region $ 221 $ 23,299 Western Region — 180,283 Other 7,193 3,580 Total $ 7,414 $ 207,162 Net loss Eastern Region $ 9,128 $ (58,424 ) Western Region (2,792 ) (159,894 ) Other (82,584 ) (95,044 ) Total $ (76,248 ) $ (313,362 ) Purchase of property, plant and equipment Eastern Region $ 17,384 $ 12,486 Western Region 2,024 780 Other 32 169 Total $ 19,440 $ 13,435 Purchase of intangibles Eastern Region $ 100 $ 760 Western Region — — Other 859 61 Total $ 959 $ 821 (1) Revenues from segments below the quantitative thresholds are attributable to an operating segment of the Company that includes revenue from the sale of CBD products throughout the United States. This segment has never met any of the quantitative thresholds for determining reportable segments nor does it meet the qualitative criteria for aggregation with the Company’s reportable segments. As of December 31, 2021 2020 Assets Eastern Region $ 224,105 $ 227,237 Western Region 106,485 109,039 Other 16,154 16,857 Total $ 346,744 $ 353,133
Summary of Disaggregation of Revenue	Year Ended December 31, 2021 2020 Revenue iAnthus branded products $ 117,617 $ 83,688 Third party branded products 64,267 48,024 Wholesale/bulk/other products 21,134 19,957 Total $ 203,018 $ 151,669

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Text Block [Abstract]
Summary of fair value hierarchy of Company's financial assets and financial liabilities	The following table summarizes the fair value hierarchy for the Company’s financial assets and financial liabilities that are re-measured As of December 3 1 As of December 31, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Financial Assets Long term investments—other 1 $ 568 $ — $ — $ 568 $ 512 $ — $ — $ 512 Financial Liabilities Derivative liabilities $ — $ — $ 16 $ 16 $ — $ — $ 245 $ 245 (1) Long-term investments – other are included in the investments balance on the consolidated balance sheets.
Summary of changes in level one finnacial assets	The following table summarizes the changes in Level 1 financial assets: Financial Assets Balance as of December 31, 2019 100 Revaluations on Level 1 instruments 412 Balance as of December 31, 2020 $ 512 Revaluations on Level 1 instruments 56 Balance as of December 31, 2021 $ 568
Summary of changes in level three financial assets and liabilities	Derivative Liabilities Balance as of December 31, 2019 1,671 Additions 3,325 Revaluations on Level 3 instruments (4,751 ) Balance as of December 31, 2020 $ 245 Revaluations on Level 3 instruments (229 ) Balance as of December 31, 2021 $ 16
Summary of long-term debt instruments at their carrying value and fair value	The following table summarizes the Company’s long-term debt instruments (Note 8) at their carrying value and fair value: As of December 31, 2021 As of December 31, 2020 Carryin g Fair Value Carryin g Fair Value Unsecured Debentures $ 57,171 $ 64,596 $ 54,905 $ 53,830 Secured Notes 134,902 176,487 115,350 134,609 Other 1,307 1,021 920 924 Total $ 193,380 $ 242,104 $ 171,175 $ 189,363

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments	The following table summarizes the Company’s contractual obligations and commitments as of December 31, 2021: 2022 2023 2024 2025 2026 Operating leases $ 7,342 $ 7,367 $ 7,501 $ 7,637 $ 7,439 Service contracts 2,705 3 — — — Long-term debt, principal (1) 168,209 12,531 66 16,654 79 Total $ 178,256 $ 19,901 $ 7,567 $ 24,291 $ 7,518 (1) The payment schedule above shows amounts payable if the conversion options are not exercised by the lender of the Company’s convertible debt instruments.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Year Ended 2021 2020 Financial Statement Line Item Accounts receivable $ — $ 140 Other long-term assets 4,552 3,358 Total $ 4,552 $ 3,498

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Income Tax Expense And Effective Tax Rates	Income tax expense (recoveries) for the years ended December 31, 2021 and 2020 consisted of the following: 2021 2020 Current income tax expense (Revised) Federal $ 21,656 $ 18,799 State 5,216 4,371 Total current income tax expense 26,872 23,170 Deferred income Federal (3,919 ) (3,625 ) State (704 ) (912 ) Total deferred income tax recoveries (4,623 ) (4,537 ) Tot al $ 22,249 $ 18,633
Summary of Effective Income Tax Rate Reconciliation	2021 2020 (Revised) Pretax loss at federal statutory rate $ (11,339 ) $ (61,893 ) State income tax expense, net of federal expense (1,435 ) (2,946 ) Non-deductible 16,516 53,554 True-up of income taxes payable 1,236 1,939 Foreign deferred taxes with no benefit recognized 502 (265 ) Other items (139 ) (409 ) Change in valuation allowance 16,908 28,653 Total income ta x expense $ 22,249 $ 18,633
Summary of Deferred Tax Assets and Liabilities	2021 2020 Deferred income Net operating loss carryforwards $ 37,896 $ 33,788 Interest expense carryforwards 29,038 20,413 Stock based compensation 9,082 7,377 Intangible assets 4,396 4,617 Property, plant and equipment 3,652 1,823 Inventories 670 88 Other items 772 557 85,506 68,663 Valuation allowance (80,070 ) (63,162 ) Deferred income 5,436 5,501 Deferred income Intangibles resulting from acquisitions (32,943 ) (37,623 ) Deferred income (32,943 ) (37,623 ) Net deferred inc ome $ (27,507 ) $ (32,122 )

Consolidated Statements of Ca_3

Consolidated Statements of Cash Flows Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Summary of Cash Payments	(a) Cash payments made on account of: Year Ended December 31, 2021 2020 Income taxes $ 4,497 $ 2,196 Interest 94 164
Summary of Changes in Other Non-cash Operating Assets and Liabilities	Year Ended December 31, 2021 2020 Decrease (increase) in: Accounts receivables $ (157) $ 2,801 Prepaid expenses 617 436 Inventories (6,898 ) (5,235 ) Other current assets 623 1,267 Other long-term assets (1,095 ) (12,755 ) Increase (decrease) in: Accounts payable 1,554 (4,107 ) Accrued and other current liabilities 21,950 33,376 $ 16,594 $ 15,783
Summary of Depreciation and Amortization of Assets	(c) Depreciation and amortization are comprised of the following: Year Ended December 31, 2021 2020 Property, plant and equipment $ 13,533 $ 10,658 Operating lease right-of-use 2,113 1,731 Intangible assets 15,394 15,531 $ 31,040 $ 27,920
Summary of Asset Write downs and Other Charges	(d) Write-downs and other charges are comprised of the following: Year Ended December 31, 2021 2020 Write-downs : Account receivable (recoveries) provisions, net $ (87 ) $ 861 Investment — 137 Operating lease right-of-use 259 — Property, plant and equipment (125 ) 2,700 $ 47 $ 3,698
Summary of significant non-cash investing and financing activities	(f) Significant non-cash Year Ended December 31, 2021 2020 Supplemental Cash Flow Information: Cashless exercise of MPX warrants recorded as derivatives $ — $ 3,325 Non-cash 1,279 565 Non-cash 1,471 — Accrued capital expenditures — 256 Non-cash — 414
Schedule Of Asset Impairment Charges [Table Text Block]	(e) Impairments are comprised of th e Year Ended December 31, 2021 2020 Impairment losses : Property, plant and equipment $ 36 $ — Right-of-use 2,161 — Intangible assets 5,170 4,100 Goodwill — 199,364 $ 7,367 $ 203,464

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Schedule of Debt Restructuring as per Restructuring Agreement for Subsequent Periods	As part of the Restructuring Support Agreement with the Secured Lenders and a majority of the Unsecured Debentureholders, dated July 1 0 Non-Convertible (in ’000s of U.S. dollars) Restructured 1 Interim Financing 2 8% Senior 3 Pro 4 Secured Lenders $ 85,000 $ 14,737 $ 5,000 48.625 % Unsecured Debentureholders — — 15,000 48.625 % Existing Shareholders — — — 2.75 % Total $ 85,000 $ 14,737 $ 20,000 100 % (1) The principal balance of the Secured Notes will be reduced to $85.0 million, which will be increased by the amount of the Interim Financing, which has a first lien, senior secured position over all of the Company’s assets, is non-convertible non-callable (2) The Secured Lenders provided $14.7 million of interim financing (“Interim Financing”) to ICM on substantially the same terms as the Restructured Senior Debt, net of a 5% original issue discount. The amounts of the Interim Financing along with any accrued interest thereon is expected to be converted into, and the original principal balance will be added to, the Restructured Senior Debt upon consummation of the Recapitalization Transaction. (3) The 8% Senior Unsecured Debentures include payment in kind at an interest rate of 8% per annum, a maturity date which will be five years after the consummation of the Recapitalization Transaction, are non-callable (4) On January 6, 2022, our Board of Directors approved the terms of a Long-Term Incentive Program recommended by the Board of Director’s compensation committee and, pursuant to which, we will allocate to certain of our employees (including executive officers) restricted stock units and option awards up to, in the aggregate, 5.75% of the fully diluted equity of the Company under the Company’s Amended and Restated Omnibus Incentive Plan dated October 15, 2018 (“LTIP Awards”) in order to attract and retain such employees. The allocations of the LTIP Awards are contingent upon, and will occur within ten days following, the closing of the Recapitalization Transaction contemplated by the Restructuring Support Agreement. All of the Company’s existing warrants and options will be cancelled and the Company’s common shares may be consolidated pursuant to a consolidation ratio which has yet to be determined.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Subsidiaries (Detail) - Subsidiaries [Member]	12 Months Ended
	Dec. 31, 2021
MPX Bioceutical ULC ("MPX ULC")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	MPX Bioceutical ULC (“MPX ULC”)	[1]
Place of Incorporation	Canada	[1]
Interest	100.00%	[1]
MPX Luxembourg SARL
DisclosureOfSubsidiaries [Line Items]
Name of Entity	MPX Luxembourg SARL	[1]
Place of Incorporation	Luxembourg	[1]
Interest	100.00%	[1]
ABACA, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	ABACA, Inc.	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
Ambary, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Ambary, LLC	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
Health For Life, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Health For Life, Inc.	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
Anthus Arizona, LLC iA AZ [Member]
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus Arizona, LLC (“iA AZ”)
Place of Incorporation	Arizona, USA
Interest	100.00%
S8 Management, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	S8 Management, LLC	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
S8 Rental Services, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	S8 Rental Services, LLC	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
Soothing Options, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Soothing Options, Inc.	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%	[1]
The Healing Center Wellness Center, Inc. THCWC [Member]
DisclosureOfSubsidiaries [Line Items]
Name of Entity	The Healing Center Wellness Center, Inc. (“THCWC”)	[1]
Place of Incorporation	Arizona, USA	[1]
Interest	100.00%
Bergamot Properties, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Bergamot Properties, LLC
Place of Incorporation	Colorado, USA
Interest	100.00%
Scarlet Globemallow, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Scarlet Globemallow, LLC
Place of Incorporation	Colorado, USA
Interest	100.00%
iAnthus Capital Management, LLC ("ICM")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus Capital Management, LLC (“ICM”)
Place of Incorporation	Delaware, USA
Interest	100.00%
GHHIA Management, Inc. ("GHHIA")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	GHHIA Management, Inc. (“GHHIA”)
Place of Incorporation	Florida, USA
Interest	100.00%
GrowHealthy Properties, LLC ("GHP")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	GrowHealthy Properties, LLC (“GHP”)
Place of Incorporation	Florida, USA
Interest	100.00%
iAnthus Holdings Florida, LLC ("IHF")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus Holdings Florida, LLC (“IHF”)
Place of Incorporation	Florida, USA
Interest	100.00%
McCrory's Sunny Hill Nursery, LLC ("McCrory's")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	McCrory’s Sunny Hill Nursery, LLC (“McCrory’s”)
Place of Incorporation	Florida, USA
Interest	100.00%
iA IT, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iA IT, LLC
Place of Incorporation	Illinois, USA
Interest	100.00%
Budding Rose, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Budding Rose, Inc.	[1]
Place of Incorporation	Maryland, USA	[1]
Interest	100.00%	[1]
GreenMart of Maryland, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	GreenMart of Maryland, LLC	[1]
Place of Incorporation	Maryland, USA	[1]
Interest	100.00%	[1]
LMS Wellness, Benefit, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	LMS Wellness, Benefit, LLC	[1]
Place of Incorporation	Maryland, USA	[1]
Interest	100.00%	[1]
Rosebud Organics, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Rosebud Organics, Inc.	[1]
Place of Incorporation	Maryland, USA	[1]
Interest	100.00%	[1]
Cannatech Medicinals, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Cannatech Medicinals, Inc.	[1]
Place of Incorporation	Massachusetts, USA	[1]
Interest	100.00%	[1]
Fall River Development Company, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Fall River Development Company, LLC	[1]
Place of Incorporation	Massachusetts, USA	[1]
Interest	100.00%	[1]
IMT, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	IMT, LLC	[1]
Place of Incorporation	Massachusetts, USA	[1]
Interest	100.00%	[1]
Mayflower Medicinals, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Mayflower Medicinals, Inc.
Place of Incorporation	Massachusetts, USA
Interest	100.00%
Pilgrim Rock Management, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Pilgrim Rock Management, LLC
Place of Incorporation	Massachusetts, USA
Interest	100.00%
CGX Life Sciences, Inc. ("CGX")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	CGX Life Sciences, Inc. (“CGX”)	[1]
Place of Incorporation	Nevada, USA	[1]
Interest	100.00%	[1]
GreenMart of Nevada NLV, LLC (GMNV)
DisclosureOfSubsidiaries [Line Items]
Name of Entity	GreenMart of Nevada NLV, LLC (GMNV)	[1]
Place of Incorporation	Nevada, USA	[1]
Interest	100.00%	[1]
iAnthus Northern Nevada, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus Northern Nevada, LLC
Place of Incorporation	Nevada, USA
Interest	100.00%
GTL Holdings, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	GTL Holdings, LLC
Place of Incorporation	New Jersey, USA
Interest	100.00%
iA CBD, LLC ("iA CBD")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iA CBD, LLC (“iA CBD”)
Place of Incorporation	New Jersey, USA
Interest	100.00%
iAnthus New Jersey LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus New Jersey, LLC
Place of Incorporation	New Jersey, USA
Interest	100.00%
Citiva Medical, LLC ("Citiva")
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Citiva Medical, LLC (“Citiva”)
Place of Incorporation	New York, USA
Interest	100.00%
iAnthus Empire Holdings, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	iAnthus Empire Holdings, LLC
Place of Incorporation	New York, USA
Interest	100.00%
FWR, Inc.
DisclosureOfSubsidiaries [Line Items]
Name of Entity	FWR, Inc.
Place of Incorporation	Vermont, USA
Interest	100.00%
Grassroots Vermont Management Services, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Grassroots Vermont Management Services, LLC
Place of Incorporation	Vermont, USA
Interest	100.00%
Pakalolo, LLC
DisclosureOfSubsidiaries [Line Items]
Name of Entity	Pakalolo, LLC
Place of Incorporation	Vermont, USA
Interest	100.00%
[1]	Entities acquired as a part of the MPX Bioceutical Corporation (“MPX”) acquisition on February 5, 2019 (the “MPX Acquisition”). During the year-ended December 31, 2020, the Company dissolved CinG-X America.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Cash And Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash	$ 13,244	$ 11,015
Restricted cash	3,334	495
Total cash and restricted cash presented in statements of cash flows	$ 16,578	$ 11,510	$ 34,821

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail)	12 Months Ended
	Dec. 31, 2021
Building [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	25 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	over the shorter of the initial term of the underlying lease plus any reasonably assured renewal terms, and the useful life of the asset
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Processing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Sale Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Sale Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	5 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	not depreciated

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Effects Of Reclassification Adjustment On The Line Items Of Consolidated Statements Of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reclassification [Line Items]
Other income	$ 1,573	$ 1,007
Revision of Prior Period, Reclassification, Adjustment [Member] | Reclassification Of Selling General And Administrative Expenses [Member]
Reclassification [Line Items]
Depreciation and amortization	10,658
Revision of Prior Period, Reclassification, Adjustment [Member] | Reclassification Of Amortization of Intangibles [Member]
Reclassification [Line Items]
Depreciation and amortization	15,531
Revision of Prior Period, Reclassification, Adjustment [Member] | Reclassification Of Other Losses [Member]
Reclassification [Line Items]
Other income	$ 169

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Summary of Effects Of the Adjustment On The Line items Within Consolidated Financial Statements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories	$ 30,447	$ 25,451
Current assets	55,401	45,623
Total assets	346,744	353,133
Accrued and other current liabilities	99,446	55,053
Current liabilities	285,821	231,879
Total liabilities	369,141	305,804
Accumulated deficit	(800,390)	(724,142)
Total shareholders' equity	(22,397)	47,329	$ 352,473
Total liabilities and shareholders' equity	346,744	353,133
Costs and expenses applicable to revenues	(91,735)	(69,829)
Gross margin	111,283	81,840
Loss from operations	(22,025)	(249,891)
Loss from operations before income tax		(294,911)
Income tax expense	22,249	18,633
Net loss	$ (76,248)	(313,362)
Change in operating assets and liabilities		12,537
Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories		30,292
Current assets		50,464
Total assets		357,974
Accrued and other current liabilities		56,381
Current liabilities		233,207
Total liabilities		307,132
Accumulated deficit		(720,629)
Total shareholders' equity		50,842
Total liabilities and shareholders' equity		357,974
Costs and expenses applicable to revenues		(64,988)
Gross margin		86,681
Loss from operations		(245,050)
Loss from operations before income tax		(290,070)
Income tax expense		19,961
Net loss		(309,849)
Change in operating assets and liabilities		9,024
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories		(4,841)
Current assets		(4,841)
Total assets		(4,841)
Accrued and other current liabilities		(1,328)
Current liabilities		(1,328)
Total liabilities		(1,328)
Accumulated deficit		(3,513)
Total shareholders' equity		(3,513)
Total liabilities and shareholders' equity		(4,841)
Costs and expenses applicable to revenues		(4,841)
Gross margin		(4,841)
Loss from operations		(4,841)
Loss from operations before income tax		(4,841)
Income tax expense		(1,328)
Net loss		(3,513)
Change in operating assets and liabilities		$ 3,513

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Summary of Effects Of Reclassification Adjustment On The Line Items Of Consolidated Statements Of Cashflows (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reclassification [Line Items]
Net cash used in investing activities	$ (21,318)	$ (14,740)
Reclassification Of Changes In Non Cash Working Capital Items [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]
Reclassification [Line Items]
Net cash used in investing activities	$ 3,246

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Summary of Effect Of The Adjsutment On The Line Items Within Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Supplies	$ 6,188	$ 5,010
Raw materials	5,641	7,047
Work in process	11,219	5,710
Finished goods	7,399	7,684
Inventories	$ 30,447	25,451
Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Supplies		8,457
Raw materials		8,857
Work in process		5,737
Finished goods		7,241
Inventories		30,292
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Supplies		(3,447)
Raw materials		(1,810)
Work in process		(27)
Finished goods		443
Inventories		$ (4,841)

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 07, 2022
Net Cash Provided by (Used in) Operating Activities	$ 16,148	$ (9,828)
Impairment loss	7,367	203,464
Net loss	(76,248)	(313,362)
Accumulated deficit	(800,390)	(724,142)
Debt instrument debt default amount	97,500
Debt instrument debt default principal amount	60,000
Debt instrument debt default accrued additional fees and interest	15,400
Restricted cash	3,334	495
Impairment of right of use asset	300
Impairment loss	5,500	4,100
Impairment loss related to property plant and equipment	$ 100	0
Reporting unit Percentage of fair value in excess of carrying amount	50.00%
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 5,200
Impairment Loss on goodwill	0	199,364
Goodwill	0	0
Sublease [Member]
Impairment loss	$ 1,800	0
License [Member]
Useful life of intangible assets	15 years
Minimum [Member] | Trademarks [Member]
Useful life of intangible assets	7 years
Minimum [Member] | Other Intangible Assets [Member]
Useful life of intangible assets	1 year
Maximum [Member]
Trade accounts receivable, Contractual maturity term	1 year
Maximum [Member] | Trademarks [Member]
Useful life of intangible assets	15 years
Maximum [Member] | Other Intangible Assets [Member]
Useful life of intangible assets	5 years
MPX New Jersey LLC [Member]
Percentage of voting equity interests acquired			100.00%
MPX New Jersey LLC [Member] | Subsequent Event [Member]
Percentage of voting equity interests acquired			100.00%
Recapitalization Transaction [Member]
Debt instrument face amount	$ 14,700
Secured Debt [Member]
Debt Instrument debt default accrued interest amount	30,900
Unsecured Debt [Member]
Debt Instrument debt default accrued interest amount	$ 9,600
Senior Secured Convertible Debentures [Member]
Debt instrument interest rate	13.00%
Convertible Unsecured Debentures [Member]
Debt instrument interest rate	8.00%
Tranche Four Secured Notes [Member] | Funds Held In Escrow [Member]
Restricted cash	$ 3,300	$ 500

Leases - Summary of Lease Cost

Leases - Summary of Lease Cost (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Total Lease costs		$ 8,722	$ 8,765
Selling, General and Administrative Expenses [Member]
Lessee, Lease, Description [Line Items]
Total Lease costs	[1]	$ 8,722	$ 8,765
[1]	Includes short-term leases and variable lease costs for the year ended December 31, 2021 and 2020.

Leases - Summary of Supplementa

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Supplemental Balance Sheet Information Related To Leases [Abstract]
Right-of-use assets	$ 30,429	$ 33,083
Lease Liabilities
Current portion of lease liabilities	7,342	7,450
Long-term lease liabilities	27,814	27,670
Total	$ 35,156	$ 35,120

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 7,342
2023	7,367
2024	7,501
2025	7,637
2026	7,439
Thereafter	57,464
Total lease payments	94,750
Less: interest expense	(59,594)
Present value of lease liabilities	$ 35,156	$ 35,120
Weighted-average remaining lease term (years)	11 years 8 months 12 days
Weighted-average discount rate	19.00%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Impairment loss on right-of-use assets	$ 2,161	$ 0
Impairment loss	7,367	203,464
Sublease [Member]
Impairment loss on right-of-use assets	300
Impairment loss	1,800	0
Other Income [Member] | Sublease [Member]
Sublease income	$ 600

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Supplies	$ 6,188	$ 5,010
Raw materials	5,641	7,047
Work in process	11,219	5,710
Finished goods	7,399	7,684
Total	$ 30,447	$ 25,451

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory	$ 0.4	$ 2
Costs and expenses of revenues	1.9	0
Inventory reserve	$ 1.9	$ 0

Property, Plant and Equipment

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Cost	$ 147,647	$ 127,426
Accumulated Depreciation	35,013	20,429
Net Book Value	112,634	106,997
Building [Member]
Property, Plant and Equipment [Line Items]
Cost	21,502	3,619
Accumulated Depreciation	1,930	754
Net Book Value	19,572	2,865
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	101,966	82,356
Accumulated Depreciation	24,221	14,325
Net Book Value	77,745	68,031
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	7,678	6,308
Accumulated Depreciation	3,512	2,292
Net Book Value	4,166	4,016
Processing Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	4,773	4,369
Accumulated Depreciation	3,022	1,635
Net Book Value	1,751	2,734
Sale Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	1,344	1,139
Accumulated Depreciation	574	421
Net Book Value	770	718
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	3,798	3,504
Accumulated Depreciation	1,754	1,002
Net Book Value	2,044	2,502
Land [Member]
Property, Plant and Equipment [Line Items]
Cost	4,293	4,293
Accumulated Depreciation	0	0
Net Book Value	4,293	4,293
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Cost	2,293	21,838
Accumulated Depreciation	0	0
Net Book Value	$ 2,293	$ 21,838

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation Expense	$ 13,500	$ 10,700
Disposal of property, plant and equipment	200	3,500
Net consideration from sale of property, plant and equipment	275	281
Gain on disposal of property, plant and equipment	100	2,700
Impairment loss on property, plant, and equipment	$ 100	$ 0

Intangible Assets - Summary of

Intangible Assets - Summary of other intangible assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Cost	$ 186,134	$ 191,927
Accumulated Amortization and Impairment	47,072	33,146
Net Book Value	139,062	158,781
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	153,272	153,273
Accumulated Amortization and Impairment	33,967	23,713
Net Book Value	119,305	129,560
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	29,100	34,620
Accumulated Amortization and Impairment	12,125	8,748
Net Book Value	16,975	25,872
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	3,762	4,034
Accumulated Amortization and Impairment	980	685
Net Book Value	$ 2,782	$ 3,349

Intangible Assets - Summary o_2

Intangible Assets - Summary of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2021USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2022	$ 15,375
2023	15,317
2024	15,317
2025	14,410
2026	$ 14,410

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Finite-lived	$ 5,170	$ 4,100
Finite-Lived Intangible Assets, Remaining Amortization Period	3 years
Amortization of Intangible Assets	$ 15,400	15,500
Conditional License [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Finite-lived		4,100
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	$ 900	$ 800

Long-Term Debt - Summary of Lon

Long-Term Debt - Summary of Long-term Debt Instruments (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021		Dec. 31, 2020
Debt Instrument [Line Items]
Beginning balance		$ 171,175		$ 142,052
Fair value of financial liabilities issued		13,216		13,072
Accretion of balance		9,057		16,962
Provision for debt obligation fees				10,339
Repayment		(68)		(11,250)
Ending balance		193,380		171,175
Secured Notes
Debt Instrument [Line Items]
Beginning balance		115,350	[1]	77,248
Fair value of financial liabilities issued		13,056	[1]	13,072
Accretion of balance		6,496	[1]	14,691
Provision for debt obligation fees				10,339
Ending balance	[1]	134,902		115,350
Stavola Trust Note
Debt Instrument [Line Items]
Beginning balance				10,800
Repayment				(10,800)
May 2019 Debentures
Debt Instrument [Line Items]
Beginning balance		23,240		22,471
Accretion of balance		793		769
Ending balance		24,033		23,240
March 2019 Debentures
Debt Instrument [Line Items]
Beginning balance		31,665		30,255
Accretion of balance		1,473		1,410
Ending balance		33,138		31,665
Other
Debt Instrument [Line Items]
Beginning balance		920		1,278
Fair value of financial liabilities issued		160
Accretion of balance		295		92
Repayment		(68)		(450)
Ending balance		$ 1,307		$ 920
[1]	This amount includes the Company’s obligation to pay an exit fee of $10.0 million that accrues interest at a rate of 13% per annum (the “Exit Fee”) under the Secured Notes.

Long-Term Debt - Summary of L_2

Long-Term Debt - Summary of Long-term Debt Instruments (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long term debt exit fee payable	$ 10.3
Debt instrument, unamortized discount	30.3	$ 30.3
Unamortized discount costs	3.2	9.5
Debt issuance costs, net	7.7	7
Unamortized debt issuance costs	2.5	3.5
Interest accrued on current and long term debt	45.6	$ 23.3
Secured Debt [Member]
Debt Instrument [Line Items]
Long term debt exit fee payable	$ 10
Interest rate percentage on the exit fee	13.00%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) $ / shares in Units, $ in Thousands	Dec. 31, 2021USD ($)Customer$ / sharesshares		Feb. 02, 2021USD ($)	Jul. 13, 2020USD ($)	Dec. 20, 2019USD ($)Customershares$ / shares	Sep. 30, 2019USD ($)shares$ / shares	May 02, 2019USD ($)$ / sharesshares	Mar. 18, 2019USD ($)$ / sharesshares	May 14, 2018USD ($)$ / shares	Dec. 31, 2021USD ($)Customer$ / sharesshares		Dec. 31, 2020USD ($)$ / shares		Jan. 07, 2022USD ($)shares	Apr. 04, 2021USD ($)	Mar. 31, 2021USD ($)	Jul. 10, 2020	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments | Customer										4,222,971
Debt instrument, convertible, conversion price | $ / shares	$ 5.92									$ 5.92
Volume weighted average trading price | $ / shares	$ 10.29									$ 10.29
Interest expense										$ 1,700		$ 3,400
Accretion expense										9,057		16,962
Long term debt default amount principal	$ 97,500									97,500
Long term debt exit fee payable principal and interest	15,400									15,400		13,800
Long term debt exit fee payable	10,300									10,300
Interest expenses incurred on exit fees										5,100
Secured debt long term fair value	242,104									242,104		189,363
Unamortized debt issuance costs	$ 2,500									$ 2,500		$ 3,500
Exercise price of warrants | $ / shares	$ 3.56					$ 1.97				$ 3.56		$ 4.06
Fair value of warrants, net of issuance costs	$ 100									$ 100		$ 200
Warrants and rights outstanding, measurement input	77.97									77.97
Debt issuance costs										$ 694		2,230
Debt instrument, interest rate																	16.00%
Long-term debt	$ 193,380									193,380		$ 171,175						$ 142,052
Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input												85
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input												0
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input												0.6
March 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Debt instrument maturity date							Mar. 15, 2023
Warrants and Rights Outstanding, Maturity Date							Mar. 15, 2022
Fair value of warrants, net of issuance costs	4,500									$ 4,500
Warrant issuance cost	$ 1,300
March 2019 Equity Warrants [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	74.7									74.7
March 2019 Equity Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	0									0
March 2019 Equity Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	2.4									2.4
May 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Debt instrument terms of interest payment							payable quarterly
Fair value of warrants, net of issuance costs	$ 2,600									$ 2,600
Warrant issuance cost	$ 400
May 2019 Equity Warrants [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input | Customer	73.6									73.6
May 2019 Equity Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input | Customer	0									0
May 2019 Equity Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input | Customer	2.3									2.3
Private Placement [Member] | March 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Interest rate on secured notes	8.00%									8.00%
Class of warrant or right, number of securities called by warrants or rights | shares								2,177,291
Exercise price of warrants | $ / shares								$ 6.43
Private Placement [Member] | May 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights | shares							1,555,207
Exercise price of warrants | $ / shares							$ 6.43
Private Placement [Member] | In Cash [Member] | March 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Percentage of total interest that can be paid through cash or in kind route								50.00%
iAnthus New Jersey LLC
Debt Instrument [Line Items]
Description about qualified financing										“Qualified Financing” means a transaction or series of related transactions resulting in net proceeds to the Company of not less than $10 million from the subscription of the Company’s securities, including, but not limited to, a private placement or rights offering.
Threshold limit of qualified financing, net proceeds not less than the subscription of securities										$ 10,000
Tranche One [Member]
Debt Instrument [Line Items]
Debt instrument, fair value disclosure									$ 26,200
Long-term debt									2,300
Tranche One [Member] | Common Class A [Member]
Debt Instrument [Line Items]
Issuance Costs										$ 4,400
Tranche One [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	88.3									88.3
Tranche One [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	0									0
Tranche One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	2									2
Tranche One [Member] | Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, date from which warrants or rights exercisable										May 14, 2021
Tranche Two [Member]
Debt Instrument [Line Items]
Debt instrument, fair value disclosure						$ 17,300
Long-term debt						300
Tranche Two [Member] | Tranche Two Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, date from which warrants or rights exercisable										May 14, 2021
Tranche Two [Member] | Tranche Two Equity Warrants [Member] | Common Class A [Member]
Debt Instrument [Line Items]
Issuance Costs										$ 300
Tranche Two [Member] | Tranche Two Equity Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	0									0
Tranche Two [Member] | Tranche Two Equity Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	1.6									1.6
Tranche Three [Member]
Debt Instrument [Line Items]
Debt instrument, fair value disclosure					$ 30,900
Tranche Three [Member] | Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, date from which warrants or rights exercisable										May 14, 2021
Tranche Three [Member] | Equity Warrants [Member] | Common Class A [Member]
Debt Instrument [Line Items]
Issuance Costs										$ 700
Tranche Three [Member] | Equity Warrants [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	74.6									74.6
Tranche Three [Member] | Equity Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	0									0
Tranche Three [Member] | Equity Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrants and rights outstanding, measurement input	1.7									1.7
Secured Debt [Member]
Debt Instrument [Line Items]
Long term debt exit fee payable	$ 10,000									$ 10,000
Long-term debt	134,902	[1]								134,902	[1]	$ 115,350	[1]					77,248
Secured Debt [Member] | Tranche One [Member]
Debt Instrument [Line Items]
Debt instrument face value									$ 40,000
Debt instrument maturity date									May 14, 2021
Debt instrument, convertible, conversion price | $ / shares									$ 3.08
Amortization of debt discount										1,000		2,600
Debt instrument beneficial conversion feature									$ 7,900
Interest expense										6,700		6,400
Accretion expense										2,400		6,000
Long term debt default amount principal												10,300			$ 60,000	$ 97,500
Long term debt default amount accrued interest	$ 3,500									$ 3,500					$ 9,600	$ 30,900
Percentage of total outstanding debt instrument including accrued and unpaid interest and fees									105.00%
Percentage of total outstanding debt instrument principal amount									90.00%
Secured Debt [Member] | Tranche One [Member] | Common Class A [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights | shares	3,891,051									3,891,051
Exercise price of warrants | $ / shares	$ 3.86									$ 3.86
Debt instrument, fair value disclosure	$ 8,600									$ 8,600
Warrants and rights outstanding, measurement input	4,800,000									4,800,000
Class of warrant or right, date from which warrants or rights exercisable										May 14, 2021
Class of warrant or right, Issued	$ 10,000									$ 10,000
Common stock, conversion basis										one
Shares issued, price per share | $ / shares	$ 2.57									$ 2.57
Class of warrant or right, number of securities called by each warrant or right | shares	1									1
Secured Debt [Member] | Tranche One [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate									3.00%
Secured Debt [Member] | Tranche One [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate									16.00%
Secured Debt [Member] | Tranche One [Member] | Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights | shares	6,670,372									6,670,372
Exercise price of warrants | $ / shares	$ 3.60									$ 3.60
Warrants and rights outstanding, measurement input | Customer	8,400,000									8,400,000
Class of warrant or right, date from which warrants or rights exercisable										May 14, 2021
Secured Debt [Member] | Tranche Two [Member]
Debt Instrument [Line Items]
Debt instrument face value						$ 20,000
Debt instrument maturity date						May 14, 2021
Interest rate on secured notes						13.00%
Interest expense										$ 3,200		3,100
Accretion expense										$ 700		1,800
Warrants and rights outstanding, measurement input	16									16
Secured Debt [Member] | Tranche Two [Member] | Tranche Two Equity Warrants [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights | shares						5,076,142
Warrants and rights outstanding, measurement input | Customer	2,600,000									2,600,000
Class of warrant or right, date from which warrants or rights exercisable						May 14, 2021
Secured Debt [Member] | Tranche Three [Member]
Debt Instrument [Line Items]
Debt instrument face value					$ 36,200
Debt instrument maturity date					May 14, 2021
Interest rate on secured notes					13.00%
Interest expense										$ 5,900		5,600
Accretion expense										$ 1,600		4,100
Warrants and rights outstanding, measurement input	16									16
Secured Debt [Member] | Tranche Three [Member] | Equity Warrants [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments | shares					22,448,415
Debt instrument, convertible, conversion price | $ / shares					$ 1.61
Class of warrant or right, number of securities called by warrants or rights | shares					10,792,508
Exercise price of warrants | $ / shares					$ 1.67
Warrants and rights outstanding, measurement input | Customer					5,100,000
Class of warrant or right, date from which warrants or rights exercisable					May 14, 2021
Issuance Costs					$ 600
Secured Debt [Member] | Tranche Four [Member]
Debt Instrument [Line Items]
Debt instrument face value				$ 14,700
Debt instrument maturity date				Jul. 13, 2025
Interest rate on secured notes				8.00%
Interest expense										$ 1,300		600
Accretion expense										400		200
Debt instrument original issue discount percentage				5.00%
Escrow deposit	$ 0									0		400
Secured Debt [Member] | Tranche Four [Member] | Prospective Default [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate on secured notes				8.00%
Secured Debt [Member] | Tranche Four [Member] | Prospective Default [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate on secured notes				16.00%
Secured Debt [Member] | Tranche Two Conversion Option [Member] | Tranche Two Equity Warrants [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments | shares						10,582,011
Debt instrument, convertible, conversion price | $ / shares						$ 1.89
New Jersey Senior Secured Bridge Notes [Member] | iAnthus New Jersey LLC
Debt Instrument [Line Items]
Debt instrument face value			$ 11,000
Debt instrument maturity date			Feb. 2, 2023
Interest rate on secured notes			14.00%
Interest expense										1,500		0
Accretion expense										300		0
Secured debt long term fair value	12,500		$ 10,300							12,500
Unamortized debt issuance costs	2,200		$ 700							2,200
Escrow deposit	$ 3,300									$ 3,300		0
New Jersey Senior Secured Bridge Notes [Member] | Prospective Recapitalization Transaction [Member] | iAnthus New Jersey LLC
Debt Instrument [Line Items]
Interest rate on secured notes			8.00%
New Jersey Senior Secured Bridge Notes [Member] | Prospective Default [Member] | iAnthus New Jersey LLC
Debt Instrument [Line Items]
Interest rate on secured notes			25.00%
March 2019 Debentures [Member]
Debt Instrument [Line Items]
Volume weighted average trading price | $ / shares	$ 10.29									$ 10.29
Unamortized debt issuance costs	$ 1,200									$ 1,200
Debt instrument, fair value disclosure	30,300									30,300
Debt instrument fees	$ 1,300									$ 1,300
Debt instrument fee issued in common shares | shares	700,000									700,000
Debt issuance costs	$ 600
Long-term debt	$ 33,138									$ 33,138		31,665						30,255
March 2019 Debentures [Member] | March 2019 Equity Warrants [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments | Customer	5,912,159
Debt instrument, convertible, conversion price | $ / shares	$ 5.92									$ 5.92
March 2019 Debentures [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument face value								$ 35,000
Debt instrument maturity date								Mar. 15, 2023
Debt instrument terms of interest payment								payable quarterly
Interest expense										$ 2,800		2,800
Accretion expense										1,500		1,400
March 2019 Debentures [Member] | Private Placement [Member] | In Cash [Member]
Debt Instrument [Line Items]
Percentage of total interest that can be paid through cash or in kind route								50.00%
May 2019 Debentures [Member]
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ 400									400
Debt instrument, fair value disclosure	22,300									22,300
Debt instrument fees														$ 400
Debt instrument fee issued in common shares | shares														100,000
Debt issuance costs	300
Long-term debt	$ 24,033									$ 24,033		23,240						22,471
May 2019 Debentures [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument face value							$ 25,000
Interest rate on secured notes	8.00%									8.00%
Interest expense										$ 2,000		2,000
Accretion expense										800		$ 800
Stavola Trust Note [Member]
Debt Instrument [Line Items]
Debt instrument maturity date	Jan. 19, 2020
Business combination liablity assumed non current debt	$ 10,800									$ 10,800
Related party transaction rate of interest	8.00%
Long-term debt																		$ 10,800
[1]	This amount includes the Company’s obligation to pay an exit fee of $10.0 million that accrues interest at a rate of 13% per annum (the “Exit Fee”) under the Secured Notes.

Share Capital - Summary of Warr

Share Capital - Summary of Warrants Activity (Detail) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants outstanding units beginning balance	49,236	49,236
Warrants outstanding units granted	0	0
Warrants outstanding units exercised	0	0
Warrants outstanding units expired	(26,596)	0
Warrants outstanding units ending balance	22,640	49,236
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price beginning balance	$ 4.06	$ 4.06
Weighted average exercise price granted		0
Weighted average exercise price exercised		0
Warrants Outstanding Weighted Average Exercise Price, Expired	3.84	0
Weighted average exercise price ending balance	$ 3.56	$ 4.06

Share Capital - Summary of Assu

Share Capital - Summary of Assumptions Used To Record Fair Value of Warrants (Detail)	Dec. 31, 2021yr	Dec. 31, 2020yr
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	77.97
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0.6
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0
Expected voltility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		85
Expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		7
Warrants [Member] | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.9	0.2
Warrants [Member] | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Warrants [Member] | Expected voltility | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	297.1	251.1
Warrants [Member] | Expected voltility | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	93.7	148
Warrants [Member] | Expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.9	0.9

Share Capital - Summary of Wa_2

Share Capital - Summary of Warrants Outstanding (Detail) - $ / shares	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2019
Class of Warrant or Right [Line Items]
Number outstanding	22,640	49,236
Weighted average exercise price	$ 3.56	$ 4.06	$ 1.97
Class Of Warrants Expire On 2021 [Member]
Class of Warrant or Right [Line Items]
Number outstanding	0	26,596
Weighted average exercise price	$ 0	$ 4.37
Class Of Warrants Expire On 2022 [Member]
Class of Warrant or Right [Line Items]
Number outstanding	20,855	20,855
Weighted average exercise price	$ 3.47	$ 3.62
Class Of Warrants Expire On 2023 [Member]
Class of Warrant or Right [Line Items]
Number outstanding	1,785	1,785
Weighted average exercise price	$ 4.57	$ 4.57

Share Capital - Summary of Pote

Share Capital - Summary of Potentially Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Common share options	10,504	11,510
Warrants	22,640	49,236
Secured notes	46,458	46,458
Debentures	10,135	10,135
MPX dilutive instruments	408	408
Total	90,145	117,747

Share Capital - Summary of Pot

Share Capital - Summary of Potentially Dilutive Securities (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Common Stock [Member]
Common shares amount	$ 16.4	$ 8

Share Capital - Summary Of Opti

Share Capital - Summary Of Option Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted units	0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance outstanding	11,510	19,578
Granted units	0	135
Exercised units	0	0
Forfeited/Expired units	(1,006)	(8,203)
Ending balance outstanding	10,504	11,510
Weighted average exercise price beginning balance	$ 4.86	$ 4.80
Weighted average exercise price granted		0.82
Weighted average exercise price exercised
Weighted average exercise price forfeited/expired	3.96	4.99
Weighted average exercise price ending balance	$ 4.95	$ 4.86
Weighted average contractual life	6 years 2 months 26 days	7 years 4 months 2 days

Share Capital - Additional Info

Share Capital - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
stock options ,granted	0
Warrants fair value	$ 100	$ 200
Fair value adjustment of warrants	$ 200	$ 4,800
Stock Issued During Period, Shares, Issued for Services	75
Payments of Stock Issuance Costs	$ 200
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 1,900
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	4 months 24 days
The Plan [Member]
Vesting period	3 years
Expiration Period	10 years
Common Class A [Member] | The Plan [Member]
Issuance of shares authorised	2,000,000
Stock Option [Member]
stock options ,granted	0
Incentive stock options , exercise price	0	0
stock options , exercised	0	0
Aggregate intrinsic value of outstanding options	$ 0	$ 0
Incentive stock options [Member]
stock options ,granted	135
Incentive stock options , exercise price	0.82
stock options , exercised	0.82
Warrant [Member]
Warrants, granted.	0	0
Warrants, exercised	0	0
Warrants, expired	26,596	0
Aggregate intrinsic value of outstanding warrants	$ 0	$ 0
Selling, general and administrative expenses
Share-based payment arrangement expense	$ 6,500	$ 11,400

Segment Information - Summary o

Segment Information - Summary of Reportable Segments (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenues		$ 203,018	$ 151,669
Gross profit		111,283	81,840
Depreciation and amortization		28,927	26,189
Asset impairments and write-downs		7,414	207,162
Net loss		(76,248)	(313,362)
Purchase of property, plant and equipment		19,440	13,435
Purchase of intangibles		959	821
Assets		346,744	353,133
Eastern Region
Segment Reporting Information [Line Items]
Revenues		128,979	91,149
Gross profit		84,863	57,549
Depreciation and amortization		16,885	14,346
Asset impairments and write-downs		221	23,299
Net loss		9,128	(58,424)
Purchase of property, plant and equipment		17,384	12,486
Purchase of intangibles		100	760
Assets		224,105	227,237
Western Region
Segment Reporting Information [Line Items]
Revenues		72,424	57,613
Gross profit		27,877	24,239
Depreciation and amortization		11,235	11,054
Asset impairments and write-downs			180,283
Net loss		(2,792)	(159,894)
Purchase of property, plant and equipment		2,024	780
Assets		106,485	109,039
Other
Segment Reporting Information [Line Items]
Revenues	[1]	1,615	2,907
Gross profit		(1,457)	52
Depreciation and amortization		807	789
Asset impairments and write-downs		7,193	3,580
Net loss		(82,584)	(95,044)
Purchase of property, plant and equipment		32	169
Purchase of intangibles		859	61
Assets		$ 16,154	$ 16,857
[1]	Revenues from segments below the quantitative thresholds are attributable to an operating segment of the Company that includes revenue from the sale of CBD products throughout the United States. This segment has never met any of the quantitative thresholds for determining reportable segments nor does it meet the qualitative criteria for aggregation with the Company’s reportable segments.

Segment Information - Summary_2

Segment Information - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 203,018	$ 151,669
iAnthus branded products
Disaggregation of Revenue [Line Items]
Revenues	117,617	83,688
Third party branded products
Disaggregation of Revenue [Line Items]
Revenues	64,267	48,024
Wholesale/bulk/other products
Disaggregation of Revenue [Line Items]
Revenues	$ 21,134	$ 19,957

Segment Information - Additiona

Segment Information - Additional Information (Detail) - Customer Concentration Risk - Revenue Benchmark - Customer	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Information [Line Items]
Entity wide revenue major customer	0	0
Customer [Member]
Product Information [Line Items]
Credit risk	10.00%

Financial Instruments - Summary

Financial Instruments - Summary of Fair Value Hierarchy of Company's Financial Assets and Financial Liabilities (Detail) - Fair Value, Recurring - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
Derivative Financial Instruments, Liabilities [Member]
Financial Liabilities
Derivative liabilities		$ 16	$ 245
Derivative Financial Instruments, Liabilities [Member] | Level 3 [Member]
Financial Liabilities
Derivative liabilities		16	245
Other Long-term Investments [Member]
Financial Assets
Long term investments - other	[1]	568	512
Other Long-term Investments [Member] | Level 1 [Member]
Financial Assets
Long term investments - other	[1]	$ 568	$ 512
[1]	Long-term investments – other are included in the investments balance on the consolidated balance sheets.

Financial Instruments - Summa_2

Financial Instruments - Summary of Changes in Level One Financial Assets (Detail) - Other Long-term Investments [Member] - Level 1 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	$ 512	$ 100
Revaluations on Level 1 instruments	56	412
Ending balance	$ 568	$ 512

Financial Instruments - Summa_3

Financial Instruments - Summary of Changes in Level Three Financial Assets and Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additions		$ 3,325
Revaluations on Level 3 instruments	$ (229)
Ending balance	16
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance		1,671
Revaluations on Level 3 instruments		$ (4,751)
Ending balance	$ 245

Financial Instruments - Summa_4

Financial Instruments - Summary of Company's Long-Term Debt Instruments at their Carrying Value and Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Carrying value	$ 193,380	$ 171,175
Fair value	242,104	189,363
Unsecured Debentures
Debt Instrument [Line Items]
Carrying value	57,171	54,905
Fair value	64,596	53,830
Secured Notes
Debt Instrument [Line Items]
Carrying value	134,902	115,350
Fair value	176,487	134,609
Other Long Term Debt
Debt Instrument [Line Items]
Carrying value	1,307	920
Fair value	$ 1,021	$ 924

Commitments - Summary of contr

Commitments - Summary of contractual obligations and commitments (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2022	$ 178,256
2023	19,901
2024	7,567
2025	24,291
2026	7,518
Operating leases [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2022	7,342
2023	7,367
2024	7,501
2025	7,637
2026	7,439
Service Contracts [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2022	2,705
2023	3
2024
2025
2026
Long term Debt Principal [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
2022	168,209
2023	12,531
2024	66
2025	16,654
2026	$ 79

Commitments - Additional Inform

Commitments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	May 23, 2019
Maximum [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
Operating leases with renewal options	15 years
Minimum [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
Operating leases with renewal options	1 year
Zia Integrated LLC [Member]
Contractual Obligation Fiscal Year Maturity Schedule [Line Items]
Aggregate line of credit			$ 15
Principal amount of the convertible promissory note	$ 0	$ 0
Drawdowns from line of credit	$ 0
Exercise date of right to termination	Aug. 5, 2021

Contingencies And Guarantees -

Contingencies And Guarantees - Additional Information (Detail) - USD ($)	Aug. 19, 2021	Jul. 15, 2021	Jan. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Jul. 10, 2020	Apr. 19, 2020	Mar. 13, 2020	Mar. 04, 2020
Contingencies And Guarantees [Line Items]
Loss contingency claim for right to receive consulting fees and punitive damages				$ 500,000
Loss Contingency, Damages Sought, Value				167,000,000
Claim for alleged payments				1,300,000
Claim for right to receive				115,000,000
Loss Contingency Accrual				5,400,000
Final Settlement Payable				1,500,000
Maximum [Member]
Contingencies And Guarantees [Line Items]
Loss Contingency, Damages Sought, Value	$ 10,000,000
Litigation Settlement, Amount Awarded to Other Party		$ 700,000		500,000
Minimum [Member]
Contingencies And Guarantees [Line Items]
Total damages claimed value	$ 1,000,000
Litigation Settlement, Amount Awarded to Other Party		$ 300,000		100,000
Claim against ICHMPX ULC And MPX [Member]
Contingencies And Guarantees [Line Items]
Loss Contingency Accrual				$ 3,000,000
Claim by prior shareholders of Grow Healthy Holdings LLC [Member]
Contingencies And Guarantees [Line Items]
Loss Contingency, Damages Sought, Value			$ 22,000,000
Loss Contingency Accrual						$ 22,000,000
Claim by security services firm against McCrory's, GHHIA, GHP, and IHF [Member]
Contingencies And Guarantees [Line Items]
Loss Contingency Accrual									$ 1,000,000
Claim by Himed LLC an equity holder and holder of unsecured debentures [Member]
Contingencies And Guarantees [Line Items]
Debt instrument face value							$ 5,000,000
Claims filed by oasis investments two master funds limited for breaching debt covenants [Member]
Contingencies And Guarantees [Line Items]
Repayment of debt								$ 25,000,000
Damages payable to former employees [Member]
Contingencies And Guarantees [Line Items]
Loss Contingency Accrual					$ 1,200,000

Related Party Transactions - Su

Related Party Transactions - Summary of Related Party Transactions (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Accounts receivable	$ 0	$ 140
Other long-term assets	4,552	3,358
Total	$ 4,552	$ 3,498

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) C$ in Millions, $ in Millions	Feb. 05, 2019USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020NIO (C$)	Jun. 30, 2017NIO (C$)
MPX NJ [Member]
Related Party Transaction [Line Items]
Company's acquisition equity interests			99.00%
Revolving Credit Facility [Member] | Hadley Ford [Member]
Related Party Transaction [Line Items]
Line of credit accrued interest rate		2.50%
Receivable with imputed interest due date		Jun. 30, 2021
Line of Credit outstanding Amount			$ 0	$ 0.4	C$ 0.5
Line of credit facility maximum borrowing capacity		$ 0.4				C$ 0.5
Remaining line of credit amount was offset by additional compensation				0.5
Revolving Credit Facility [Member] | Hadley Ford [Member] | Termination Agreement [Member]
Related Party Transaction [Line Items]
Line of credit amount partially offset against compensation		$ 0.3
MPX [Member] | Elizabeth Stavola [Member]
Related Party Transaction [Line Items]
Accounts recievable due from a related party	$ 0.7
MPX [Member] | Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Related party receivable was converted into a loan facility	$ 10
Line of credit accrued interest rate	16.00%
Receivable with imputed interest due date			Dec. 31, 2021
Line of Credit outstanding Amount			$ 4.6	3.2
Line of Credit accrued interest			$ 0.9	$ 0.3

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense and Effective Tax Rates (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current income tax expense
Federal	$ 21,656	$ 18,799
State	5,216	4,371
Total current income tax expense	26,872	23,170
Deferred income tax recoveries
Federal	(3,919)	(3,625)
State	(704)	(912)
Total deferred income tax recoveries	(4,623)	(4,537)
Total income tax expense	$ 22,249	$ 18,633

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Pretax loss at federal statutory rate	$ (11,339)	$ (61,893)
State income tax expense, net of federal expense	(1,435)	(2,946)
Non-deductible items	16,516	53,554
True-up of income taxes payable	1,236	1,939
Foreign deferred taxes with no benefit recognized	502	265
Other items	(139)	(409)
Change in valuation allowance	16,908	28,653
Total income tax expense	$ 22,249	$ 18,633

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred income tax assets
Net operating loss carryforwards	$ 37,896	$ 33,788
Interest expense carryforwards	29,038	20,413
Stock based compensation	9,082	7,377
Intangible assets	4,396	4,617
Property, plant and equipment	3,652	1,823
Inventories	670	88
Other items	772	557
Gross	85,506	68,663
Valuation allowance	(80,070)	(63,162)
Deferred income tax assets	5,436	5,501
Deferred income tax liabilities
Intangibles resulting from acquisitions	(32,943)	(37,623)
Deferred income tax liabilities	(32,943)	(37,623)
Net deferred income tax liabilities	$ (27,507)	$ (32,122)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) C$ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2021NIO (C$)	Dec. 31, 2021USD ($)
Federal statutory rate	21.00%	21.00%
Domestic Tax Authority [Member]
Operating loss carryforwards				$ 98.9
Expiration period	2035 through 2038
Operating loss carryforwards subject to limitations on use	$ 2.1
Domestic Tax Authority [Member] | CANADA | Minimum [Member]
Open tax year	2018
Domestic Tax Authority [Member] | CANADA | Maximum [Member]
Open tax year	2020
Domestic Tax Authority [Member] | UNITED STATES | Minimum [Member]
Open tax year	2013
Domestic Tax Authority [Member] | UNITED STATES | Maximum [Member]
Open tax year	2020
Domestic Tax Authority [Member] | Tax Period Two Thousand And Thirty Four Through Two Thousand And Thirty Seven [Member]
Operating loss carryforwards				11
Domestic Tax Authority [Member] | Indefinite Period [Member]
Operating loss carryforwards				87.9
State and Local Jurisdiction [Member]
Expiration period	2035 through 2040
Operating loss carryforwards subject to limitations on use	$ 0.4
State and Local Jurisdiction [Member] | Minimum [Member]
Open tax year	2018
State and Local Jurisdiction [Member] | Maximum [Member]
Open tax year	2020
State and Local Jurisdiction [Member] | Tax Period Two Thousand And Thirty Five Through Two Thousand And Forty [Member]
Operating loss carryforwards				$ 84.2
Canada Revenue Agency [Member]
Expiration period	2025 through 2041
Canada Revenue Agency [Member] | Tax Period Two Thousand And Thirty Four Through Two Thousand And Forty [Member]
Non-capital loss carryforwards		$ (106.7)	C$ 135.2

Consolidated Statements of Ca_4

Consolidated Statements of Cash Flows Supplemental Information - Summary of Cash Payments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 4,497	$ 2,196
Interest	$ 94	$ 164

Consolidated Statements of Ca_5

Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Non-Cash Operating Assets and Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Increase (Decrease) in Operating Capital [Abstract]
Decrease (increase) in accounts receivables	$ (157)	$ 2,801
Decrease (increase) in prepaid expenses	617	436
Decrease (increase) in inventories	(6,898)	(5,235)
Decrease (increase) in other current assets	623	1,267
Decrease (increase) other long-term assets	(1,095)	(12,755)
Increase (decrease) in accounts payable	1,554	(4,107)
Increase (decrease) in accrued and other liabilities	21,950	33,376
Total	$ 16,594	$ 15,783

Consolidated Statements of Ca_6

Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization Of Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation And Amortization [Line Items]
Depreciation and amortization	$ 31,040	$ 27,920
Property, plant and equipment
Depreciation And Amortization [Line Items]
Depreciation and amortization	13,533	10,658
Operating lease right-of-use assets
Depreciation And Amortization [Line Items]
Depreciation and amortization	2,113	1,731
Other intangible assets
Depreciation And Amortization [Line Items]
Depreciation and amortization	$ 15,394	$ 15,531

Consolidated Statements of Ca_7

Consolidated Statements of Cash Flows Supplemental Information - Summary of Asset Write-downs and Other Charges (Detail) - Write-downs and other charges - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Asset Write Downs And Other Charges [Line Items]
Asset write-downs and other charges	$ 47	$ 3,698
Accounts receivable provisions
Asset Write Downs And Other Charges [Line Items]
Asset write-downs and other charges	(87)	861
Investment
Asset Write Downs And Other Charges [Line Items]
Asset write-downs and other charges	0	137
Operating lease right-of-use assets
Asset Write Downs And Other Charges [Line Items]
Asset write-downs and other charges	259	0
Property, plant and equipment
Asset Write Downs And Other Charges [Line Items]
Asset write-downs and other charges	$ (125)	$ 2,700

Consolidated Statements of Ca_8

Consolidated Statements of Cash Flows Supplemental Information - Summary of Significant Non-Cash Investing and Financing Activities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Non Cash Investing And Financing Activities Disclosure [Line Items]
Accrued capital expenditures	$ 0	$ 256
Non-cash consideration transferred from property, plant and equipment	0	414
New Jersey Senior Secured Bridge Notes [Member] | iAnthus New Jersey LLC
Cash Flow Non Cash Investing And Financing Activities Disclosure [Line Items]
Non-cash consideration transferred	1,471	0
MPX Warrants [Member]
Cash Flow Non Cash Investing And Financing Activities Disclosure [Line Items]
Cashless exercise of MPX warrants recorded as derivatives	0	3,325
Tranche One Secured Notes [Member] | Secured Debt [Member]
Cash Flow Non Cash Investing And Financing Activities Disclosure [Line Items]
Non-cash consideration transferred	$ 1,279	$ 565

Consolidated Statements of Ca_9

Consolidated Statements of Cash Flows Supplemental Information - Summary Of Asset Impairment Charges (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Property, plant and equipment	$ 36	$ 0
Right-of-use assets	2,161	0
Intangible assets	5,170	4,100
Goodwill	0	199,364
Asset Impairment Charges	$ 7,367	$ 203,464

Subsequent Events - Schedule of

Subsequent Events - Schedule of Debt Restructuring as per Restructuring Agreement for Subsequent Periods (Detail) $ in Thousands	Jul. 10, 2020USD ($)
Restructured Senior Debt [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	$ 85,000
Restructured Senior Debt [Member] | Secured Lenders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	85,000
Interim Financing [member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	14,737
Interim Financing [member] | Secured Lenders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	14,737
8% Senior Unsecured Debentures [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	20,000
8% Senior Unsecured Debentures [Member] | Secured Lenders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	5,000
8% Senior Unsecured Debentures [Member] | Unsecured Debentureholders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor	$ 15,000
Proforma Common Equity [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor percentage	100.00%
Proforma Common Equity [Member] | Secured Lenders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor percentage	48.625%
Proforma Common Equity [Member] | Unsecured Debentureholders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor percentage	48.625%
Proforma Common Equity [Member] | Existing Shareholders [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Troubled debt restructuring debtor percentage	2.75%

Subsequent Events - Schedule _2

Subsequent Events - Schedule of Debt Restructuring as per Restructuring Agreement for Subsequent Periods (Parenthetical) (Detail) - USD ($) $ in Millions	Jan. 06, 2022	Jul. 13, 2020	Jul. 10, 2020
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Debt instrument interest rate stated percentage			16.00%
Long-Term Incentive Program percent	5.75%
8% Senior Unsecured Debentures [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Debt instrument interest rate stated percentage		8.00%
After Consummation of Recapitalization Transaction [member] | 8% Senior Unsecured Debentures [Member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Debt instrument maturity date		five years
Interim Financing [Member] | ICM [member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Proceeds from short term loans		$ 14.7
Restructured Senior Debt [member] | Payment in Kind (PIK) Note [member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Debt instrument interest rate stated percentage		8.00%
Restructured Senior Debt [member] | Secured Convertible Notes [member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Decrease in pricipal balance of debt instrument		$ 85
Restructured Senior Debt [member] | After Consummation of Recapitalization Transaction [member]
Troubled Debt Restructuring, Debtor, Subsequent Periods [Line Items]
Debt instrument maturity date		five years

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 07, 2022	Oct. 24, 2019
MPX NJ [Member]
Equity Method Investment, Ownership Percentage	99.00%
iAnthus New Jersey LLC | MPX NJ [Member]
Equity Method Investment, Ownership Percentage			1.00%	99.00%
iAnthus New Jersey LLC | Maximum [Member] | MPX NJ [Member]
Equity Method Investment, Ownership Percentage			100.00%
MPX New Jersey LLC [Member]
Percentage of voting equity interests acquired			100.00%
Recapitalization | Selling, general and administrative expenses
Restructuring costs incurred	$ 7.4	$ 6.8
Restructuring costs incurred to date	$ 14.2